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ABSTRACT
425 million people have diabetes worldwide, and by 2045 this number is
estimated to increase to 629 million. The risk for cardiovascular diseases such as
cardiomyopathy, hypertension, and atherosclerosis increase 5 and 2-fold for diabetic
women and men respectively. Diabetic cardiomyopathy (DCMP) is a ventricular
dysfunction that occurs in patients with diabetes independent of coronary artery disease,
hypertension or valvular abnormalities. Hyperglycemia and dyslipidemia cause metabolic
disturbances that adversely affect myocardial cells and extracellular matrix. These
modifications alter overall myocardial structure and cardiac function, which can lead to
heart failure.
As of now there is no specific marker for this disease and diagnosis is the same as
other cardiomyopathies. Elucidating early stages of this disease is vital for early
diagnosis, treatment, and possible therapy targets. Currently, rodent models and 2D cell
cultures have been employed to analyze DCMP, however there are notable differences
between rodents and humans that provide challenges when studying DCMP and cell
cultures lack an extracellular matrix and dynamic environment crucial to the progression
of this disease.
Our overall goal was to use tissue engineering to bridge this gap by developing
platforms to study pathological mechanisms at the cellular and extracellular level. We
examined cardiac tissue engineered constructs in: (1) a perfusion 3D Kube
minibioreactor and (2) an electromechanical bioreactor customized in our lab. Each
platform contained decellularized myocardium seeded with human cardiomyocytes for
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two weeks; “diabetic” conditions were simulated by increased glucose concentration. We
were able to better mimic physiological conditions with our electromechanical
bioreactor, compared to static and non-diabetic conditions, as well as to 2D cell culture.
Methods for detecting cellular and matrix changes associated with DCMP were validated
in a type 1 diabetic rodent model. Our tissue engineering platform shows promise for
unveiling early cellular and matrix modifications in DCMP. This system could also be
useful for studying human cells in other cardiac diseases, test treatments, and
precondition myocardial-like tissue prior to implantation.
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CHAPTER 1: REVIEW OF LITERATURE
1.1 Introduction
The total global economic burden of diabetes mellitus in 2017 was estimated at
$850 billion.1 425 million people have diabetes worldwide, and by 2045 this number is
estimated to increase to 629 million.1 The risk for cardiovascular disease increases 5 and
2 fold for diabetic women and men respectively.2 Diabetics have higher instances of
cardiovascular

disease

such

as

diabetic

cardiomyopathy,

hypertension,

and

atherosclerosis, with elevated occurrences of myocardial infarctions and strokes within
these patients due to atherosclerotic plaque ruptures.3 Diabetic cardiomyopathy (DCMP)
can manifest in diabetic patients and it is estimated 19-26% of diabetic patients
experience heart failure.4 DCMP is a ventricular dysfunction that occurs in patients with
diabetes independent of coronary artery disease, hypertension or valvular abnormalities.
Excessive utilization of circulating free fatty acids (FFA) creates a highly oxidative
environment that supersedes the endogenous antioxidant defense mechanism of cells,
leading to oxidative stress, lipotoxicity, autophagy, and apoptosis of cardiomyocytes. The
hyperglycemic environment causes the formation and accumulation of advanced
glycation endproducts (AGEs) in the extracellular matrix, fibrosis, and, lastly, heart
failure.5 As of now, mainly rodent models and two dimensional (2D) cell cultures have
been employed to analyze DCMP. However, there are notable differences between
rodents and humans that provide challenges when studying DCMP and 2D cultures lack a
dynamic, three dimensional (3D) environment crucial to the progression of this disease.6
There is a need for a more accurate model to investigate DCMP for early diagnosis and

1

test potential therapies. This gap can be bridged with the development of a reproducible,
native-like tissue engineered model of the myocardium utilizing the tissue engineering
paradigm of combining a scaffold, cells, and biochemical and physical stimuli.
1.2 The Heart and Myocardium
The heart is responsible for pumping blood throughout the body to supply
oxygen, nutrient, and waste exchange. It is a highly stressed organ as it beats between 60
and 100 beats per minute. It is comprised of four chambers, four heart valves, and utilizes
a network of blood vessels in the circulatory system for transportation.7 Within the body,
the heart is located left to the midline posterior to the sternum and rotated slightly so that
its right border is located more anteriorly, and the left border is located more posteriorly.
A fibrous sac and serous lining called the pericardium, surrounds the heart to provide an
almost frictionless environment for the continuous movement of this organ. The normal
adult human heart is typically 12cm in length, 8cm wide, 6cm thick, and weighs between
250 and 350 grams.8

Figure 1.1: The layers of the heart wall.7
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The heart wall consists of three layers; the epicardium, myocardium, and
endocardium with blood vessels and capillaries incorporated (Figure 1.1). The outer
epicardium is comprised of epithelium and connective tissue and fat; the middle
myocardium is made of mainly cardiomyocytes (CMs) and fibroblasts (FBs); and the
inner endocardium contains endothelium and areolar connective tissue.7
1.2.1 The Extracellular Matrix of the Myocardium
The extracellular matrix (ECM) of healthy myocardium is a dynamic
environment, undergoing constant, balanced turnover in its normal state. It is made of
collagens (type I, III, IV, V, and VI), elastin, glycoproteins (laminins, fibronectin,
periostin, fibromodulin, and vitronecin), proteoglycans (versican, lumican, and biglycan),
glycosaminoglycans (hyaluronic acid and dermatan sulfate), and matricellular proteins.9

Figure 1.2: Scanning electron microscopy (SEM) image of acellular myocardium, illustrating the
collagenous network of the ECM that supports native cells.10 Arrows=cell voids.

3

These extracellular molecules are secreted by cells in the heart, mainly the FBs,
and provide mechanical and biochemical support of the cells (Figure 1.2) by facilitating
cell adhesion and differentiation. Collagens provide strength and resilience for the highly
stressed environment and proteoglycans are receptors on cell surfaces. Proteoglycans
provide cushioning for the cells and glycosaminoglycans are responsible for storage of
growth factors and cell hydration.11

Figure 1.3: Roles of MMPs in physiological processes.12

4

Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteases
produced by cells. MMPs play an important role in ECM turnover by breaking down
various ECM proteins, such as collagens and elastin.9 They are also vital for tissue
invasion, immune responses, vascularization, and cell proliferation, migration, and
differentiation (Figure 1.3). Resident growth factors in the ECM are proteolytically
cleaved and released by MMPs for cellular uptake.12 Besides degradation of ECM,
MMPs can degrade cell receptors to terminate migratory signaling and cell migration.
Within the human body, 23 types of MMPs are known to exist, along with 4 endogenous,
homologous tissue inhibitors of MMPs (TIMPs). TIMPs are endogenous and bind to
MMPs at a 1:1 ratio. MMPs are controlled at multiple levels including messenger
ribonucleic acid (RNA) expression, activation of proenzyme to the active form, and
binding of TIMPs.12
1.2.2 The Cells of the Myocardium
The myocardium is composed of two main cell types, the cardiomyocytes (CMs)
and fibroblasts (FBs) (Figure 1.4). Even though CMs occupy the largest volume in the
heart, around 75%, their populations are only around 30-40%. FBs make up the majority
of the heart’s population. Smaller populations of vascular smooth muscle cells (SMCs)
and endothelial cells (ECs) are also found, as they comprise the vascular network in the
myocardium.13
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Figure 1.4: Hematoxylin and eosin staining of human myocardium.14 40x; purple=nuclei;
pink=cytoplasm, tissue.

Figure 1.5: Cardiomyocyte cross section.7
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CMs allow for contraction of the ventricles and atria. Myocytes in the ventricle
are long and narrow, and can be 10 to 25 um in diameter and 50 to 100 um in length,
while myocytes in the atrium are oval and are less than 10 um in diameter and around 20
um in length.15 CMs have one or two nuclei and form Y-shaped branches that join to
adjacent CMs via intercalated discs (Figure 1.5).7 Intercalated discs allow for force to be
transmitted from one CM to another, while gap junctions allow for electrical transmission
between cells.8 Mitochondria account for 60% of the cell volume, providing cellular
energy through the production of adenosine 5’-triphosphate (ATP) and can also prevent
intercellular calcium overload through calcium uptake.15

Figure 1.6: Excitation-contraction of a cardiomyocyte.14
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Contraction of CMs is possible through an intricate network of proteins organized
in sarcomeres, which are composed of thick and thin filaments (Figure 1.6). Myosin and
actin comprise thick and thin filaments, respectively. CM contraction is set in motion by
an action potential that travels along the sarcolemma into the transverse tubule (T-tubule)
and depolarizes the cell membrane. This in turn opens calcium channels to allow calcium
in the cell. Intracellular calcium rapidly increases as the sarcoplasmic reticulum releases
even more calcium in response. Calcium binds to troponin-C on the thin filaments,
inducing a conformational change and exposing myosin binding sites on the actin
filament. This binding leads to ATP hydrolysis, which results in a conformational change
of the actin-myosin complex and a sliding of the filaments, causing the sarcomere to
shorten. Shortening in this unit is responsible for the overall contraction of the cell. The
sarcomere length is restored with lowered cytosolic calcium concentration and a ATP
binding to the myosin head at the end of this cycle.8
The structural integrity of the heart relies mainly on FBs, as they are very
proliferative and produce interstitial collagen for the maintenance of the ECM. They also
contribute to cardiac development, cell-signaling, and electro-mechanical function. FBs
are interspersed throughout the myocardium.13 Cardiac FBs are elongated, contain one
nucleus, and have high cellular activity as they have an intricate endoplasmic reticulum
and a large Golgi apparatus. FBs are very dynamic in nature and can change phenotypes
during injury states to become myofibroblasts. Myofibroblasts enhance the inflammatory
response by secreting cytokines during injury. Cardiac injuries such as ischemia can
initiate FB phenotypic changes and recruitment to the site of injury, leading to fibrosis16
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Blood vessels within the heart supply the myocardium and resident cells with
oxygen and nutrients. Due to its great energy demands, the myocardium is highly
vascularized, with an average distance of 12um between capillaries.17 They are
comprised of FBs, SMCs, and ECs. ECs line the lumen or tunica intima of the vessel,
forming a non-thrombogenic surface (Figure 1.7) SMCs form the tunica media, the layer
surrounding the tunica intima, and FBs sheath the outermost layer of the vessel, the
adventitia or tunica externa. These cells communicate with each other via physical
contact and soluble or secreted molecules to regulate vessel maintenance, as well as tone
and blood pressure.18

Figure 1.7: Structure of a blood vessel wall.
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1.3 Cardiac Disease of the Myocardium
1.3.1 Coronary Artery Disease and Myocardial Infarction
Coronary artery disease is characterized by atherosclerosis in one or both
coronary arteries, which are the main vessels that supply the myocardium with oxygen
and nutrients. This can lead to ischemia of the myocardium, myocardial infarction, and
even sudden death.3 As atherosclerotic plaque ruptures within the artery due to
inflammatory mechanisms; a thrombus forms and occludes the vessel. Necrosis of the
tissue supplied by this vessel quickly occurs, followed by inflammation. As mentioned
before, FBs are very dynamic and during an injury state become myofibroblasts. After a
MI, macrophages in the infarcted region secrete transforming growth factor-beta (TGFβ), which guides FBs to myofibroblasts. Myofibroblasts remodel the infarcted tissue by
secreting collagen I and III, creating a fibrous patch.19

FIGURE 1.8: Illustration of ventricular CM hypertrophy compensation after MI and ischemia of
the myocardium, leading to irreversible dilation followed by heart failure.20
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After myofibroblasts remodel the infarct area, the overall mechanics of the heart
are altered. CMs become hypertrophied to compensate for the lost CMs and maintain
original cardiac output (FIGURE 1.8).20 This compensation works short term, however
over time CM hypertrophy and fibrosis of the ECM, lead to enlargement of the heart or
dilation, and may end in heart failure.21
1.3.2 Cardiomyopathies
Cardiomyopathy is defined as a disease of the heart muscle, mainly of the left
ventricle. It is marked by decreased systolic and/or diastolic function of the heart, which
leads to heart failure. Main classifications of cardiomyopathy include; dilated,
hypertrophic, and restrictive (Figure 1.9), and arrhythmogenic, without noticeable heart
size or shape change.22

Figure 1.9: Gross morphological changes associated with dilated, hypertrophic, and restrictive
cardiomyopathies. Dilated cardiomyopathy is marked by ballooning; hypertrophic by noticeably
thickened walls; and restrictive by stiffened walls.23
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Dilated cardiomyopathy is defined as ventricular chamber dilation and systolic
dysfunction with normal ventricular thickness in the absence of abnormal loading
conditions, such as hypertension.24 It has an estimated prevalence of up to 1:250 and 3050% of cases are genetic in nature.25–28 Some cases are idiopathic and other causes
include myocardial infections, systemic disorders, drugs and toxins, and endocrine and
metabolic disorders.29–31 Clinical presentations include cardiac arrhythmias, heart failure,
and in some cases sudden death.32 Hallmarks of this cardiomyopathy include an increase
in ventricular mass, affecting mainly the left ventricle, a ballooning of the heart into a
spherical shape, and floppy myocardium. There is loss of a proper apex leading to
altered blood flow mechanics and a reduced ejection fraction, which can lead to mural
thrombi.30,33 At the microscopic level, interstitial and perivascular fibrosis is present in
the myocardium and the endocardium.32 CMs are the most affected, with myofibril loss
and varying morphological changes. Many CMs undergo apoptosis which results in a
mixture of hypertrophic CMs with enlarged nuclei and thin, lengthened CMs in the
myocardium.34
Hypertrophic cardiomyopathy is defined as the presence of increased
ventricular wall thickness or mass in the absence of any loading conditions sufficient to
cause observed abnormality.33 It has a prevalence of 1:500 worldwide.35 The etiology is
genetic, with sarcomeric hypertrophic cardiomyopathy being the most common, followed
by mitochondrial disorders and metabolic or storage disease.36,37 Genetic screening is
important for diagnosis, as myocardial hypertrophy precedes symptoms and the disease
can remain stable and under the radar.38 Clinical presentations include left ventricular

12

dysfunction, heart failure, and sudden death.39,40 In this form of cardiomyopathy, the
myocardium is thick, ranging from mild, 13-15mm, to massive, 30mm.33 Focal
hypertrophy is found throughout the myocardium, mainly focused on the basal anterior
septum and anterolateral free wall, which can lead in extreme cases to myocardial
bridging. The mitral valve is often affected with enlarged leaflets, hypertrophied and
abnormally positioned papillary muscles, and short chordae, which can lead to subaortic
obstruction.40 Microscopically in the myocardium there is an overall spatial
disorganization of myofibers and single CMs, with replacement and interstitial
fibrosis.35,37 Morphologically, CMs have increased y-branching and side-to-side
junctions, a whorled appearance, and herringbone pattern. CMs also have decreased
distribution of desmin, intercalated disks, and z-bands.33 Vascular cells are also affected,
smooth muscle cells become hypertrophied and intimal thickening and perivascular
fibrosis are present.35
Restrictive cardiomyopathy is defined as reduced diastolic relaxation of the left
or both ventricles that can occur from many different pathologies. Diastolic filling is
inhibited with an increase in ventricular filling pressure, while systolic function remains
unchanged.41,42 Causes are wide ranging and can be isolated or systemic in nature, as well
as idiopathic. Amyloidosis, sarcoidosis, scleroderma, storage disease, toxicity,
postirradiation therapy, and genetic mutations are some known causes.42,43 Clinical
presentations include diastolic dysfunction and heart failure. Biatrial enlargement occurs
with unchanged atrial-ventricular valves and left ventricular wall thickness. Volume of
the ventricles can remain unchanged or be decreased. Due to the ranging pathologies
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leading to restrictive cardiomyopathy, macro and micro changes can vary, depending on
the cause. For example, in sarcomeric restrictive cardiomyopathy, the atria are
disproportionately dilated compared to normal ventricular size, while in amyloidosis, the
atria are only mildly enlarged and the left ventricular wall can be affected in some
cases.41 Microscopically, interstitial fibrosis of myofibers and CMs are found in
sarcomeric restrictive cardiomyopathy, while CMs in amyloidosis are atrophic. Amyloid
deposits are the hallmark of amyloidosis and can be found histologically in the
myocardium, endocardium, valves, arteries and veins.33
Arrhythmogenic cardiomyopathy is rare and defined as a genetic heart disease
mainly affecting the right ventricle. It is a progressive myocardial injury where CMs are
replaced by fibroadipose tissue.44,45 Worldwide it is estimated to have prevalence up to
1:2000.46 Mainly desmosomal proteins of intercalated disks are mutated, such as
armadillo proteins plakiglobin (JUP) and desmocollin-2 (DSC2), however other proteins,
such as TGF-β3 and desmin can be affected.46,47 Clinical manifestations include
ventricular arrhythmias, heart failure and an increase in sudden death, especially in
juveniles and athletes.44,48 With this cardiomyopathy there is no noticeable heart size or
shape change. The external two-thirds of the right ventricle is normally effaced, and in
some cases the left ventricle can be as well. The pulmonary infundibulum and outer right
ventricle wall are the areas most affected.33 In this disease, a mixture of atrophic and
hypertrophic CMs with vacuolar degeneration are found in the myocardium, separated by
interstitial fibrosis. CMs are lost and replaced by fibrous or fibroadipose tissue.47
Lymphocytes and macrophages can also be found in the diseased myocardium.33

14

1.3.3 Diagnosis and Treatments
Coronary artery disease and cardiomyopathy are often diagnosed via symptoms or
physical examination. They are verified through echocardiograms, electrocardiograms,
cardiac angiograms, cardiac magnetic resonance imaging (MRI), cardiac positron
emission tomography (PET), and occasionally an endomyocardial biopsy.22 Symptoms
include fatigue, weakness, shortness of breath, palpitations, light headedness, fainting,
and chest pain. Treatments can include lifestyle changes such as diet and exercise and
drugs, including but not limited to, blood thinners, angiotensin converting enzyme (ACE)
inhibitors, diuretics, corticosteroids, aldosterone, angiotensin II, beta, or calcium channel
blockers.3 When a myocardial infarction occurs, speedy reperfusion is critical in limiting
infarct size and percutaneous coronary intervention with balloon angioplasty with or
without a stent is often utilized to reopen the occluded vessel. Coronary artery bypass is
another treatment method to supply blood to the ischemic tissue.21 Pacemakers,
implanted cardioverter defibrillators, and left ventricular assist devices may be utilized
depending on the severity.3 Unfortunately, these treatments will only slow the
progression of these diseases and they will ultimately lead to heart failure where the only
treatment is whole heat transplantation.
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Figure 1.10: Diagram highlighting alterations in the myocardium caused by a diabetic
environment that lead to DCMP.
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1.4 Diabetic Cardiomyopathy
Diabetic cardiomyopathy (DCMP) is defined as a ventricular dysfunction that
occurs in diabetic patients independent of coronary artery disease, hypertension, or
valvular abnormalities.49,50 Metabolic alterations caused by high glucose and
dyslipidemia contribute to the onset and progression of DCMP (Figure 1.10). Within the
ventricle, especially the left, fibrosis and microvascular disease changes the normal
structure and function of myocardium. Normal cellular function is changed by a
metabolism shift, leading to lipid peroxidation and the buildup of reactive oxygen species
(ROS), which cause apoptosis and autophagy.50 Diabetic patients have higher instances
of coronary artery disease, as well as hypertension and atherosclerosis, due to this
hyperglycemic and hyperlipidemic milieu.3
1.4.1 Diabetes Mellitus
Normally, the body regulates blood glucose levels via a feedback loop to either
release insulin or glucagon, to maintain homeostasis. During high glucose levels, islet of
Langerhans beta cells in the pancreas (Figure 1.11) release insulin (Figure 1.12). Insulin
binds to tyrosine kinase insulin receptors on target cells, inserting glucose transporters
(GLUT4) on the cell surface for glucose transport (Figure 1.13). The liver then converts
excess glucose to glycogen for storage and other cells begin to take up glucose via
GLUT4. During low glucose levels, islet alpha cells release glucagon, which signals the
liver to convert glycogen to glucose and release it into the blood (Figure 1.14). However,
this homeostasis is disrupted with the metabolic disease diabetes, leading to not only
prolonged hyperglycemia, but also a plethora of health issues.51
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Figure 1.11: Anatomy of the pancreas and islet cells.7

There are two main types of diabetes. Type 1 diabetes is known as insulin
dependent diabetes or juvenile onset diabetes. It is characterized by destruction of beta
cells in the pancreas. This can occur due to an autoimmune disorder triggered by genetic
or environmental factors. Some cases of type 1 diabetes are idiopathic. Type 2 diabetes is
known as insulin resistant diabetes and is characterized by a decrease insulin secretion
and synthesis. Type 2 diabetes is the most prevalent, accounting for 90% of diabetes.
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This is due to the rise in the epidemic of obesity, especially in developing countries.
Distribution of abdominal fat in obese type 2 diabetic patients, leads to alterations in cell
receptors accompanied by resistance to endogenous insulin.51,52
Treatment of both types focus on control of blood glucose, as mismanagement of
blood glucose levels by the patient lead to health problems, such as cardiovascular
disease, and in extreme mismanagement cases, death.3 Type 1 diabetes is treated with
insulin therapy, accompanied by close monitoring of blood glucose levels with
glucometers to determine insulin dosage, either through a pump or syringe. Blood
glucose is also monitored in type 2 diabetes, however due to the nature of this type,
lifestyle changes, such as healthy eating habits and exercise can be used to treat and even
reverse this type.53 Unlike type 1 diabetes, there is a wide spectrum associated with this
type. When lifestyle changes are not enough, oral drugs such as metformin,
sulfonylureas, thiazolindinediones (TZD), glucagon-like peptide 1 (GLP-1), and
dipeptidyl peptidase inhibitors (DPP-4) may be used, and in extreme cases, insulin.
Metformin increases insulin sensitivity and glucose uptake, while decreasing glucose gut
absorption and hepatic gluconeogenesis. Sulfonylureas raise insulin release in beta cells.
TZDs are peroxisome proliferator-activated receptor gamma agonists that improve
insulin sensitivity, lipid profile, and blood glucose control. GLP-1 activates GLP-1
receptors, which boosts glucose-dependent insulin secretion and decreases glucagon
secretion. DPP-4 or gliptins raise incretin levels (GLP-1), which has the same outcome as
GLP-1 treatments.54
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Figure 1.12: Glucose regulation of insulin secretion in pancreatic beta cells.55

Figure 1.13: Translocation of GLUT4 to the target cell’s membrane via tyrosine kinase insulin
receptor binding to insulin for cellular glucose uptake.55
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Figure 1.14: Blood glucose homeostasis.56

1.4.2 Clinical Diagnosis and Treatment of Diabetic Cardiomyopathy
Diagnosis of DCMP is the same as any cardiomyopathy described earlier, and as
of now is unable to be diagnosed in asymptomatic patients.57 Currently the only
serological biomarker that can be used is brain natriuretic peptide, however it is a marker
associated with several cardiac diseases.58 Studies are ongoing to determine biomarkers,
specifically microRNAs, that could be useful for DCMP diagnosis.59,60
Once patients are diagnosed with DCMP, emphasis is placed on glucose control
and cardiomyopathy treatments are prescribed based on the individual.61 For glucose
control, type 1 diabetic patients continue with insulin therapy, while extra precautions are
taken with management prescriptions for type 2 diabetics.62 Sulfonylureas are often not
prescribed as they may not function, due to heart failure being an insulin resistant state.3
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TZDs increase fluid retention, so they are cautioned for use with class I and II heart
failure and not recommended for use with class III and IV heart failure by the New York
Heart Association (Table 1.1).58 DCMP can be treated with, but not limited to, lifestyle
changes, ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, beta
blockers, calcium channel blockers and diuretics.63,64 Depending on the severity and the
symptoms, combinations of these can be used.65 Calcium channel blockers are not
recommended for heart failure patients with type 1 diabetes.3 As the DCMP worsens,
depending on the progression and individual, devices such as implantable cardioverter
defibrillators, cardiac resynchronization devices, left ventricular assist devices, and even
whole heart transplants may be employed. However, surgeries are risky, and one of the
many criteria is that the patient have established glycemic control.3 Unfortunately, there
is no cure for DCMP, like other cardiomyopathies.

New York Heart Association Classifications of Heart Failure
Class I Cardiac disease, but no symptoms and no limitations in normal physical activity
Class II Mild symptoms and slight limitation during ordinary activity
Class III Significant limitation in activity due to symptoms- comfortable only at rest
Class IV Severe limitations- symptoms even while at rest
Table 1.1: Classifications of heart failure from the New York Heart Association.66

Understanding of the progression of DCMP can be broken down into three stages.
Molecular and cellular events from hyperglycemia and dyslipidemia cause structural
alterations that lead to myocardial dysfunction and heart failure (Table 1.2).3,65 However,
this is a general understanding of the occurrence of this disease and as new knowledge of
DCMP is brought to light, the progression and alterations may not be this rigid. Clinical
findings hint at the possibility of two phenotypes associated with either type 1 diabetes or
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type 2 diabetes, which are dilated cardiomyopathy with reduced left ventricular ejection
fraction and restrictive cardiomyopathy with preserved left ventricular ejection fraction,
respectively.67

Table 1.2: General progression of DCMP highlighted by three stages.3

1.4.3 Metabolic Shift in Diabetes
As mentioned before, left ventricular CMs have very high-energy demands.
Within the human body, the heart utilizes the largest amount of energy per gram of tissue,
roughly 20 times its own weight per day.68 Approximately 70 percent ATP produced in
the resting heart is due to FFA oxidation.68 Uptake of FFAs into the CM is mediated via
three transporters; cluster of differentiation 36 (CD36), fatty acid transport protein 1, and
plasma membrane form of fatty acid binding protein. CD36 is stored in intracellular
vacuoles (~50%) where it can be recruited to the sarcolemma membrane for the uptake of
FFA under conditions such as muscle contraction, and stimulation by insulin and
caffeine.68 Physiologically, there is flexibility in the heart, allowing for shifts in the
utilization of glucose and free fatty acids (FFA). Nutrients increase myocardial insulin
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signaling and plasma insulin levels within the body. This leads to translocation of
GLUT4 and CD36 to the CM sarcolemma, for glucose and FFA uptake, respectively, in
order to supply myocardial energy substrates.57

Figure 1.15: Pathophysiology of diabetes mellitus on energy metabolism in the heart.68

In the diabetic heart, this plasticity is lost, due to increased FFA in the circulation
and depletion of GLUT4 (Figure 1.15).69 High FFA levels activate transcription factor
peroxisome proliferator-activated receptor alpha (PPARα) in the CM nucleus, leading to
increased myocardial FFA oxidation and utilization via upregulation of CD36 expression,
thus upregulating mitochondrial fatty acid beta-oxidation.70 Insulin signaling is
suppressed as insulin receptor substrate 1 (IRS1) is inhibited from accumulation of FFA
and their derivatives.68 CD36 is highly expressed on the sarcolemma, while GLUT4
returns to its intracellular location.71 In this unbalanced environment, mitochondrial
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oxidation capacity is exceeded and mitochondrial fission is increased, resulting in
mitochondrial fragmentation with an accumulation of ROS, which can lead to
apoptosis.72,73 Increased circulating FFA also lead to inhibition of pyruvate
dehydrogenase through pyruvate dehydrogenase kinase 4 (PDK4), impairing glycolysis
and causing the buildup of glycolytic intermediates and intracellular lipids, such as
ceramides.74 This lipid accumulation decreases contractile function, hinders physiological
autophagy, and impairs insulin signaling, leading to increased apoptosis within the
myocardium.58 These metabolic alterations ultimately lead to ROS production,
lipotoxicity, CM death and hypertrophy, altered calcium handling and myocardial
fibrosis.57
1.4.4 Oxidative Stress
Within the healthy cardiovascular system, a balance exists between ROS
production and their removal by antioxidants.75 Production of ROS is a naturally
occurring process within the body and sources of ROS arise from non-enzymatic,
enzymatic, and mitochondrial reactions.76 Non-enzymatic formation of ROS occurs via
autoxidation of glucose as well as a reaction between protein and glucose (Figure
1.19).64,77 Sources of enzymatic formation of ROS are nitric oxide synthase (NOS),
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and xanthine oxidase.64
The mitochondrial respiratory chain also provides a source of ROS, during oxidation
phosphorylation.78 In the physiological state, ROS play an important role in cell
signaling, biosynthesis, and is an anti-infectious defense and a balance exists between
ROS formation and antioxidant defense mechanisms.79 Enzymatic and non-enzymatic
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defense mechanisms in the body eliminate ROS. Enzymatic mechanisms such as
superoxide dismutase (SOD) and glutathione reductase are important in removal of
ROS.80 Non-enzymatic antioxidants include glutathione, coenzyme Q10, and vitamins A,
E, and C.76 This balance is important, as elevated ROS leads to oxidative stress, a
harmful state which can alter cellular function and lead to cell death.49
As mentioned before, the loss of metabolic plasticity in the diabetic heart leads to
increased FFA oxidation in CM mitochondria followed by ROS accumulation. Due to
high energy demands of CM, it is theorized that the mitochondria are responsible for the
majority of ROS production in this diseased state.81 This influx of ROS supersedes
endogenous antioxidant defense mechanisms, leading to oxidative stress.82 Constant
oxidative stress degenerates proteins, deoxyribonucleic acid (DNA), and lipids within the
cells (Figure 1.16) causing cellular dysfunction that leads to apoptosis and autophagy.83

Figure 1.16: Schematic of pathologic outcomes of mitochondrial ROS production and prolonged
oxidative stress due to hyperglycemia and hyperlipidemia.84
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1.4.5 Impaired Cardiomyocyte Contraction
Intracellular calcium in the CM is responsible for excitation-contraction coupling
during cellular contraction at the micro-scale and myocardial compression at the macrolevel.85 Calcium enters the cell through L-type calcium ion channels (ICa-L), which
activates calcium release from endoplasmic reticulum and sarcoplasmic reticulum via
ryanodine receptors (RyRs), leading to increases of calcium that binds to troponin C,
activating contraction. Relaxation of CMs occurs through the release of calcium from
troponin C, followed by calcium uptake via sarcoplasmic/endoplasmic reticulum Ca+2ATPase (SERCA), Na+2/Ca+2 exchanger (NCX), sarcolemmal Ca+2-ATPase, and
mitochondrial Ca+2 ATP uniport.86
In the diabetic environment, dysfunctional intracellular calcium signaling and
lower expressions of ion channels, SERCA, NCX, RyRs, and decreased myofilament
calcium sensitivity in CMs lead to an imbalance in calcium homeostasis (Figure 1.17).87
Hyperglycemia upregulates protein kinase C (PKC) and downregulates protein kinase A
(PKA), which causes depression of outward potassium currents (Ito) and ICa-L and L-type
calcium

channel

expression.88

High

glucose

also

increases

phosphorylated

phospholamban (PLB) which reduces activity of SERCA and decreases overall SERCA
and NCX expression.89 Calcium homeostasis is furthermore upset with the dysfunction of
RyR due to hyperphosphorylation, causing leakage of calcium during diastole and
depletion of sarcoplasmic reticulum calcium stores.74 Sensitivity of myofibrils to calcium
are compromised with phosphorylation of troponin I and T from increased PKC
activation, which leads to slower cross-bridge cycling.90 AGEs produced in high glucose
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conditions irreversibly bind between calcium handling proteins, such as SERCA and
RyR, leading to their inactivation.91 Myosin switches from the alpha to beta isoform in
diabetes slows actin-myosin kinetics and depresses myosin and myofibrillar ATPase
activity.92 N2B to N2BA titin ratios shift towards N2BA, a more elastic isoform, and titin
becomes hyperphosphorylated, causing contraction dysfunction.92 Overall, these
alterations in calcium handling are detrimental to cardiac efficiency and are obvious in
slowed CM contraction and relaxation, prolonged action potential duration, and reduced
shuttling of intracellular calcium.87

FIGURE 1.17: Alterations within the cardiomyocyte in diabetic cardiomyopathy that cause
contraction dysfunction and reduced cardiac efficiency.92

1.4.6 Endoplasmic Reticulum Stress
The endoplasmic reticulum (ER), comprised of rough and smooth regions, is the
main site for synthesis and processing of proteins and lipids in the secretory pathway.
Within the closed ER lumen, newly polypeptide chains synthesize, fold and mature.7
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These posttranslational modifications and folding interactions optimize protein function
before correctly folded proteins are exported to the Golgi apparatus and transported to
intracellular organelles or extracellular membrane. The ER also is a storage site for
calcium.93 Accumulation of unfolded or misfolded protein within the lumen of the ER
induces ER stress. This mechanism of action is triggered to restore homeostasis and can
lead to the unfolded protein response (UPR).94 Conditions such as radiation, hypoxia,
ischemia, oxidation, dysregulation of calcium, altered metabolism, or DNA mutations
lead to ER stress.95
Increased circulated FFAs and hyperglycemia cause a metabolic shift,
accumulation of ROS, and issues of calcium handling within the CM.96 These in turn lead
to ER stress and the UPR to control protein quality. There are three main pathways that
are utilized during the UPR; inositol-requiring enzyme 1 (IRE1), protein kinase RNA-like
ER kinsase (PERK), and activating transcription factor 6 (ATF6) pathways (Figure
1.18).97 In the unstressed state, these sensors are bound to binding protein (BiP) and
remain inactive.98 When misfolded proteins are present in the ER lumen, BiP unbinds
from IRE1, PERK, and ATF6, allowing it to attach to misfolded proteins to serve as a
chaperone.99 Misfolded proteins have exposed hydrophobic regions, which BiP readily
binds to.97 Once IRE1 is activated, it becomes phosphorylated by PKA and splices X-box
binding protein 1 (XPB1) messenger RNA, yielding transcription factor XBP1s for
expression of UPR target genes, upregulation of ER chaperones, and exportation and
degradation of misfolded proteins.100 IRE1 also activates Jun N terminal kinase (JNK)
which can lead to apoptosis and autophagy.101 After unbinding of BiP, PERK
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phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) reduces protein
translation, while increasing activating transcription factor 4 (ATF4), which induces
transcription of CCAAT/-enhancer-binding protein homologous protein (CHOP). ATF4
and CHOP upregulate genes involved in protein synthesis and ER associated degradation
(ERAD).93 PERK also phosphorylates nuclear factor (erythroid-derived 2)-related factor2
(Nrf2), which turns on genes that combat oxidative stress.102 In the ATF6 signaling
pathway, unbinding of BiP frees ATF6 from the ER and is translocated to the Golgi
apparatus, where it is cleaved by resident proteases.97 This cleaved cytoplasmic domain
activates genes involved in lipid biosynthesis, protein folding, ER expansion, and
ERAD.103 Under prolonged ER stress, these pathways lead to autophagy and apoptosis.96

Figure 1.18:

Illustration of ER stress and the UPR, leading to the activation of the ATF6,

IRE1, and PERK pathways in response.101,104
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1.4.7 Extracellular Matrix Changes
During hyperglycemia, an influx of glucose leads to the formation of advanced
glycation end-products (AGEs), form irreversible cross-links within lipids and proteins,
such as collagen, laminin, and elastin, and cause fibrosis.105 This cross-link is formed by
the Maillard reaction via a Schiff base and Amadori product (Figure 1.19). Matrix
metalloproteinases are unable to degrade these irreversible ECM modifications, causing
an imbalance in physiological ECM turnover.106 AGE formation can induce cardiac FB
proliferation and elevated collagen production.107 Accumulation of AGEs lead to vascular
disease, as when it binds to a receptor for AGEs (RAGE), it increases endothelial
permeability to macromolecules.108 Oxidative stress upregulates RAGE expression,
which in turn causes increased NADPH oxidase expression, mitochondrial oxidase
activation, and suppresses endogenous antioxidant activity.109 This establishes a positive
feedback loop between ROS formation and RAGE expresssion.106
Inhibition of matrix metalloproteinase (MMP) activity, macro and microvascular
disease, and altered AGE and RAGE expression lead to myocardial thickening and
fibrosis (Figure 1.20).111,112 Fibrosis causes the myocardium to stiffen and vascular
disease decreases nutrient transport within the myocardium, inducing cell death in this
vicious cycle.50 As CMs undergo apoptosis and autophagy, the ventricle must continue to
pump at the same rate, so the surviving CMs must compensate for ones that have died
off. To do so CMs enlarge and become hypertrophied.113 As they are continually
overstressed mechanically and as more CMs continue to die in the toxic diabetic
environment, the myocardium function gradually declines, ending in heart failure.
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Figure 1.19: Mechanism for AGE formation via glycoxidation.110

Figure 1.20: Autopsy of a heart with DCMP. (A) Gross anatomy showing hypertrophy of the left
ventricle. (B) Hematoxylin and eosin staining showing fibrosis and cardiomyocyte hypertrophy
within the left ventricle.113
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1.4.8 Potential Antioxidant Therapies
Researchers have started focusing on antioxidant therapies to combat elevated
ROS in within the diabetic environment.114,115 One method of interest is increasing
intracellular SOD content. This is a favorable countermeasure; however, SOD isoforms
are very large, making them difficult to permeate the cells, and they have a very short
half-life. Mito-TEMPO ((2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)
triphenylphosphonium chloride) is a mimetic form of SOD, that is more stable and
smaller, allowing it to overcome these barriers (Figure 1.21).116 Ni et al. tested mitoTEMPO in type 1 diabetes streptozotocin (STZ) and type 2 diabetes db/db mouse models.
They found in both animal models that daily injections of mito-TEMPO for 30 days
inhibited mitochondrial ROS generation, prevented intracellular oxidative stress levels,
decreased apoptosis, and reduced myocardial hypertrophy in diabetic hearts.78

Figure 1.21: Structure of mito-TEMPO.117
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Rutin is another appealing antioxidant. It is a citrus flavonoid found in a variety
of plants (Figure 1.22).118 Bhandary et al. investigated a series of flavonoids in a study to
determine if all or any would have a protective effect on ischemic/reperfused rat hearts.
To test different concentrations of flavonoids, harvested rat hearts, subjected them to
ischemia, reperfused them, and then perfused treatments through them. They found that
rutin enhanced SOD activity and had consistent protective effects in ischemic/reperfusion
injury.80 In other studies performed by Saklani et al. and Wang et al. on STZ induced
type 1 diabetic rats, rutin treatments significantly protected hearts against diabetic
oxidative stress, improved electrocardiography parameters, apoptosis, and inflammation
in the diabetic hearts.118,119

Figure 1.22: Structure of Rutin.120
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Coenzyme-Q10 is an antioxidant that is endogenously synthesized and is a
lipophilic cofactor of the mitochondrial electron transport chain (Figure 1.23). It is
available as a non-prescription oral dietary supplement and has been shown to be
beneficial when used with other therapies for chronic heart failure.121 Blasio et al. studied
the effect of coenzyme-Q10 on an exacerbated diabetic cardiomyopathy mouse model
with reduced phosphoinositide 3-kinase (PI3K) signaling, which upregulates NADPH
oxidase. 6-week-old dominant negative PI3K p110α mice were treated with STZ and
after 4 weeks were treated with coenzyme-Q10. Within this aggravated model, coenzyme
Q10 reduced left ventricular diastolic dysfunction, CM fibrosis and hypertrophy,
expression of atrial natriuretic peptide, connective tissue growth factor, and β-myosin
heavy chain.77

Figure 1.23: Reduction of ubiquinone (coenzyme-Q10) to ubiquinol through semiquinone
intermediate.122
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There has also been a shift towards naturally occurring plant-based antioxidants,
such as curcumin, garlic, and broccoli.123 Turmeric powder, with the active polyphenol
curcumin (Figure 1.24), has been used as a spice for cooking and medicinal purposes in
Asia for thousands of years.124 Yu et al. treated type 1 diabetic induced STZ rats with oral
administrations of curcumin and found that it attenuated myocardial dysfunction, cardiac
fibrosis, AGE accumulation, oxidative stress, apoptosis, and inflammation in the diabetic
rat hearts.125 Sahebkar et al. performed a meta-analysis of eight randomized controlled
clinical trials and found curcumin treatments significantly reduced pro-inflammatory
cytokine tumor necrosis factor alpha (TNFα).126

Figure 1.24: Structure of curcumin.127

There are many ongoing investigations of other potential antioxidants not only for
treatment of cardiac disease in diabetes, but also cardiovascular diseases in general,
cancer, arthritis, autoimmune disorders, phycological diseases, neurological issues, etc.114
Many of these antioxidants are on the market in non-prescription supplemental forms,
however additional research into dosage and effect, as well as monitoring of production
need to be performed. Antioxidants target sources of many diseases, making it a
promising therapeutic avenue.
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1.5 Cardiac Tissue Engineering
Tissue-engineered models have been used to address discrepancies between
animals and humans to investigate diseased states. These organotypic models aim to
replicate specific architecture and relevant physiological function of the tissue for
analysis.128 This is useful for studying disease progression, as well as drug screening and
treatment testing. Myocardial tissue engineering combines cells, scaffolds, and cues to
create a structure and network similar to the native tissue. Many groups are looking to the
promise of tissue-engineered myocardium, not only for the study of normal and diseased
myocardium, but also for the hope of creating functional myocardium as a treatment for
heart disease.129 This overlap has led to the rise of different approaches to develop tissueengineered myocardium that have the crossover potential to be used for modeling and
diseased tissue replacement.
1.5.1 Cardiac Scaffolds
Scaffolds for cardiac tissue engineering are utilized to provide an environment
comparable to native myocardial ECM for cells to attach and align, interact with each
other, transmit load, and conduct electric signals. The scaffold must also be able to be
remodeled by the cells (i.e.- biodegradable) and have similar mechanical properties to
withstand physiological cyclic strains and stresses.130 It should be biocompatible and
have porosity that promotes vascularization and diffusion of oxygen and nutrients to
support the seeded cells.131
Biomaterials utilized for cardiac scaffolds include, synthetic, natural, and
combination. Several natural materials employed include collagen, fibrin, hyaluronic
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acid, Matrigel, and preparations of native heart matrix. Some synthetic materials applied
include polyesters such as poly(lactic acid) and poly(glycolic acid), poly(lactones),
polyurethanes, and polysebasic acid.130 Combinations of synthetic and natural materials
such as poly(e-caprolactone) and gelatin or collagen have also been used.132 Scaffolds
can further be categorized by method of fabrication such as hydrogel, prefabricated
matrices, decellularized tissue, and cell sheets. Advantages and disadvantages that should
be taken into consideration when deciding on a method to use (Table 1.3).131
Scaffold
Hydrogels
Prefabricated
Decellularized
Cell Sheets

Source
Natural, Synthetic and Mixed
Natural, Synthetic and Mixed
Natural

Natural

Advantages
Disadvantages
In-situ injection of cells
Fragile, prone to breakage
Lessened immune response
Easy to engineer and manipulate 3D forms Optimal porosity needs to be maintained
Exact ECM structure difficult to create
Vascularization
Difficulties reseeding
Immune response eliminated
Native ECM protiens retained
Easy to scale up in 3D form
Fragile and difficult to handle
Easy to manipulate
Limited thickness

Table 1.3: Types of scaffold fabrication methods with materials that can be used and some
advantages and disadvantages of each.131

Hydrogels are produced by crosslinking water-soluble polymers. They can be
made from natural or synthetic materials or combinations. Cells can integrate and grow in
the scaffold.131 To increase cell anchoring and integration, growth factors and peptides,
such as arginylglycylaspartic acid (RGD) for cell adhesion. Hydrogels are favorable
vehicles for cardiac cell and/or growth factor in-situ injection, as it can increase delivery
efficiency via protective encapsulation and catheters can be used for transport,
eliminating the need for invasive surgery and use of drugs or anesthesia.131 Encapsulation
by hydrogels can also alleviate immunogenic responses post implantation. For cardiac
applications, this scaffold type is limited by its ability to withstand physiological forces
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seen in the heart.133 Wang et al. injected crosslinker tetraaniline-polyethylene glycol
diacrylate and thiolated hyaluronic acid, along with adipose derived stem cells and
plasmid DNA encoding endothelial nitric oxide synthases (eNOs) nanocomplexes into
the myocardium of rat infarct models. In rats there was an increase in ejection fraction,
shortened QRS interval, smaller infarction size, less fibrosis, and higher vessel density
within the hearts.134 Tang et al. injected human cardiac stem cells in thermosensitive
poly(N-isopropylacrylamineco-acrylic acid) nanogel into mouse and pig myocardial
infarction models. In mice and pigs treated with cells and hydrogels, cardiac function was
preserved and scar size was decreased.135
Prefabricated matrices are useful for cardiac tissue engineering, as mechanical
properties, behavior, porosity, size, and degradability are tailorable.131 These scaffolds
can be made from natural, synthetic, or combination materials. Pores of these scaffolds
can be tailored by methods such as, porogen leaching, freeze drying, phase separation,
and electro-spinning. Difficulties can arise in using preformed matrices, as it is difficult
to exactly recapitulate ECM and overall organ structure with this method.131 Gu et al.
fabricated cardiac patches with electro spun elastomeric polyester urethane urea and
polyester ether urethane urea with incorporated recombinant adeno-associated virusgreen fluorescent protein (GFP) labelled- to test addition and release of viral vectors in
infarcted rat models. GFP was expressed even after 12 weeks and mechanical support
provided by the scaffold improved remodeling and provided support to the compromised
infarct tissue.136 Tsui et al. constructed cardiac scaffolds from electroconductive-acid
modified silk fibroin-poly(pyrrole) substrates patterned with nanoscale ridges and
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topography similar to native ECM. Human induced pluripotent stem cell (iPSC)
cardiomyocytes were cultured on this material for 21 days and showed increased cellular
organization and sarcomere development, with increased connexin-43 expression.137
Tissue decellularization (decell) is a method that uses the organ itself to provide
the 3D structure of interest through detergent washes to remove cells and cellular
material, leaving the ECM and vasculature intact. Decelling is a favorable method, as
immunogenic material is removed and native ECM, such as collagen, elastin, and
laminin, is retained, allowing for patient specific cells to be integrated into the native
scaffold to create an individually tailored tissue.138 One obstacle to overcome with this
scaffold is homogenous cell seeding. Perea-Gil et al. tested decellularized porcine
myocardium and human pericardium that were reseeded with or without porcine adipose
mesenchymal stem cells in porcine myocardial infarct models. Both scaffolds with or
without cells restored function of myocardium post infarction and integrated with the
underlying tissue via neovascularization.139 Decell is based on the idea that nature is the
best engineer. Recently, other vascularized things in nature, such as plants, have been
researched. Gershlak et al. decellularized spinach and parsley leaves and roots were
performed and seeded with human cells. Human iPSC cardiomyocytes seeded showed
contractile function and calcium handling capabilities over the course of 21 days.140
Cell sheets are considered a scaffold free approach and are employed to
overcome the obstacle of low cell concentrations and inflammatory reactions of scaffolds.
They are fabricated by culturing cells on poly-N-isopropylacrylamide, a temperature
sensitive polymer, until they are confluent.141 At 37 degrees Celsius, the cell culture
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dishes are hydrophobic and cell adhesive. The monolayer of cells can be detached from
the polymer at 32 degrees Celsius, leaving the ECM and proteins intact. These fragile
sheets can then be layered to a maximum thickness of 80um to form tissue.131 Shudo et
al. implanted a bilayered cell sheet of rat endothelial progenitor cells (EPCs) and rat
mesenchymal stem cells differentiated into smooth muscle cells (SMCs) into a rat model
of ischemic cardiomyopathy. Rats treated with the EPC-SMC cell sheet had increased
mature vessel density, decreased cardiac fibrosis, increased left ventricular ejection
fraction, and decreased left ventricular dimensions.142 Sakaguchi et al. fabricated 10um
thick cell sheets with neonatal rat CMs at 30 degrees Celsius in order to slow metabolism
and allow for myocardial tissue formation and prevascularization. Lower temperature
cultured cell sheets were implanted under the skin of nude rats and developed denser
prevascular networks compared to cell sheets cultured in normal conditions, showing
promise for cardiac applications.143
1.5.2 Cardiac Cell Sources
To develop functional myocardium for cardiac tissue engineering applications,
there are several cell sources for consideration. Some sources are acceptable for
implantation, while others are only suitable for disease modeling and screening for
individual patient therapies. Allogenic sources include CMs, embryonic stem cells
(ESCs), cardiac progenitor cells (CPCs), and cardiac stem cells (CSCs). Autologous
sources include adipose derived stem cells (ADSCs), skeletal myoblasts, bone marrow
derived stem cells (BMDSCs), and iPSCs (FIGURE 1.25).131 Allogenic sources have
been investigated, however complications arise with activation of the immune response.
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CPCs and CSCs are difficult to source, as they are estimated to make up 1% of total cells
in the heart. It is also problematic acquiring CMs from healthy hearts, as they will be
used for whole organ transplantation.132 There are ethical concerns with ESCs and when
transplanted in vivo, tumors can form and they may induce arrhythmias.144

FIGURE 1.25: Diagram of potential allogenic and autologous cell sources for cardiac tissue
engineering.131

Autologous skeletal myoblasts have been investigated for transplantation
treatments of diseased myocardium, as they are easy to isolate, resistant to ischemia and
fatigue. However, with skeletal myoblast transplantation there is an increased risk of
arrhythmias as they fail to structurally integrate into the myocardium and beat
independently of neighboring CMs.144 BMDSCs are another potential source from which
mesenchymal stem cells (MSCs) and EPCs can be isolated from. MSCs are easy to
isolate, can differentiate into CM-like cells in vivo and in vitro, however they have a low

42

differentiation efficiency.145 They have been shown to improve left ventricular ejection
fractions in animal myocardial infarction models when directly injected into infarct or
when

administered

intravenously.146

EPCs

have

been

shown

to

increase

neovascularization and cardiac function in infarct models, though low numbers limit their
use.147 iPSCs can be derived from adult cells, however this is a long, costly process, with
low efficiency of 0.01-0.1 percent.132 Problems arise with the use of iPSCs in vivo, as
there are concerns with tumor formation and iPSCs differentiated into CMs from patients
with cardiomyopathy have been shown to retain diseased phenotypes.148 ADSCs are easy
to isolate and are widely available within the body. In preclinical studies, they have been
shown to decrease infarct size and survival. In the PRECISE trial in Europe ADSC
treated patients with ischemic cardiomyopathy had a reduction in inducible ischemia and
improvement in peak oxygen consumption at 18 months.149
1.5.3 Cardiac Bioreactors
Merging scaffolds and cells with a bioreactor, certain conditions can be met to
produce a more physiologically relevant environment to precondition myocardial-like
tissue prior to implantation or create models for the study of disease states.
Preconditioning increases cell functionality, as well as guides cells towards myocardial
cell lineages such as CMs.150 Physiological myocardial environment recapitulation in a
bioreactor requires addition of elements such as, perfusion, electrical stimuli, and
mechanical loading, which can be added to necessary controlled conditions such as pH,
temperature, and nutrients.129,151 If the thickness of the myocardial-like tissue is greater
than ~150um, perfusion is necessary for oxygen diffusion.17
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It has been established that electrical stimulation affects cell alignment,
differentiation, metabolic activity, protein synthesis, connexin 43 expression, conduction
velocity, calcium handling, and force generation.150 Physiological electrical properties
such as rectangular shape and 2ms duration at 5V/cm and 1Hz are successful in inducing
these changes.152 Radisic et al. cultured neonatal rat CMs on collagen sponges and
subjected them to an electrical stimulus (2 ms, 5 V/cm, 1 Hz), comparable to native
myocardium for 5 days utilizing carbon rods. Cells were aligned and coupled;
intercalated discs, gap junctions, myofibrils, and T-tubules formed; and important
proteins such as troponin I, α-actinin, connexin 43, α- and β-myosin heavy chain
increased.153
Mechanical strain is also important for CM alignment and maturation.
Zimmerman et al. mechanically loaded (cyclic stretch at 10%, 2 Hz) neonatal rat CMs
seeded on collagen I scaffolds for 7 days and found that CMs more closely resembled
adult myocardial tissue when compared to 6-day old native neonatal rat myocardium.
They observed morphological changes such as a basement membrane, well developed Ttubules, cell alignment along the construct and increases in myofilaments, sarcomeric
organization, gap junctions, desmosomes, adherens junctions.154
Electrical and mechanical stimuli combined improve CM functional properties
over electrical or mechanical stimulation alone. Morgan and Black subjected neonatal rat
CMs in fibrin gel on latex tubing to electrical (rectangular pulse, 1ms, 3V/cm, 1Hz) and
mechanical (5% stretch, 50% duty cycle, 1Hz) stimulation in an electromechanical
bioreactor they constructed (Figure 1.26) for 14 days. They found that combined
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electromechanical stimuli enhanced myocardial-like tissue function by increasing
expression of SERCA2a, troponin T, protein kinase B (Akt), proteins responsible for cellcell communication and contractility.155

Figure 1.26: Electromechanical bioreactor produced in the Black Laboratory.155

1.5.4 Current Diabetic In Vivo and In Vitro Cardiac Models
Animal models are currently used to understand early cardiac alterations in
diabetes and heart failure, while cadaveric hearts have been used to study end stages heart
failure in diabetic patients. Animal models are useful, however there are many
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physiological discrepancies between humans and animal models.156 Rodent models,
particularly rat and mouse, are the typical choice for diabetic cardiac research, as they are
relatively inexpensive, easy to house and care for.156 Mouse models are employed as they
are easy to manipulate genetically.74 Type 1 diabetic rodent models such as the
streptozotocin (STZ) induced diabetes in rat or mouse model, OVE26 mouse, and Akita
diabetic mouse are common for cardiac diabetes studies.156 Standard type 2 diabetes
models include the Zucker diabetic fatty rat (ZDF), db/db mouse, and ob/ob mouse.6
While these models have been helpful in determining alterations that could be occurring
in diabetic myocardium, and have been widely accepted, there are major discrepancies
between humans and the rodent models. Rodents have a higher heart rate, differing
electrophysiological properties of CMs, and varying circulating lipid concentrations when
compared to humans.6 One of the major discrepancies often overlooked for rodent
models are differences in the immune response when compared to humans. Diabetes is a
prolonged inflammatory disease.65 Taking into consideration marked differences seen
among host immune responses in human patients and rodent subcutaneous implants, there
most assuredly are differences between rodent models and patients in this extended
inflammatory disease.157 Inconsistencies also exist in the progression of cardiac
alterations in these diabetic rodent models and within the models themselves. Depending
on the lineage of the rodent, genetic manipulation, and severity of obesity and diabetes,
some models are more susceptible to changes and show a rapid progression of diabetes
and heart failure.6 For example, when comparing type 2 diabetic models, cardiac
efficiency is markedly lower for db/db and ob/ob mice, but does not change for ZDF
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rats.158–160 In the Akita type 1 diabetic model it has been shown depending on the study
that cardiac size can remain the same or increase.161,162 Disparities may arise depending
on the sex of the animal. Akita male mice are usually more favorable for diabetes
research as female Akita mice have less pronounced hyperglycemia when compared to
their male counterparts.163
In vitro models have been employed to study cardiac alterations in diabetes and
changes that occur in specific cell types, however their models have either lacked a
dynamic 3D environment with an ECM or utilized animal cells instead of human
cells.148,164 Song et al. statically cultured rat neonatal cardiomyocytes on collagen
scaffolds in either low (1g/L) or high (4.5g/L) glucose with or without insulin (20µM) for
8 days. They saw poor electric properties and an increased ratio of myosin heavy chain
isoform β to α in high glucose cultures.164 Drawnel et al. cultured human iPSC derived
cardiomyocytes, from two type 2 diabetic patients and a non-diabetic patient and
subjected them for two days to either a manufacturer’s maintenance medium without
glucose or a “diabetic” medium with glucose (10mM), as well as endothelin-1 (10nM)
and cortisol (1µM) to dull insulin sensitivity. iPSC-CMs from type 2 diabetic patients
showed baseline cardiomyopathy (CM hypertrophy, loss of sarcomeric integrity) without
being cultured in “diabetic” medium and normal iPSC-CMs cultured in “diabetic”
medium showed baseline cardiomyopathy as well.148
1.6 Conclusions
The risk for cardiac disease is dramatically increased in diabetic patients. This is
due to the diabetic environment, as hyperglycemia and dyslipidemia cause metabolic
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disturbances that adversely affect myocardial cells and ECM. These modifications
aggregate to alter overall myocardial structure and cardiac function, leading to DCMP.
As of now there is no specific marker for this disease and diagnosis is the same as other
cardiomyopathies. Elucidating early stages of this disease is vital for determining markers
for early diagnosis, treatment, and possible therapy targets. As of now, animal models
and 2D studies have been utilized to understand early changes associated with DCMP,
however there are discrepancies with animal models and 2D studies fail to recapitulate
the ECM and dynamic environment. Tissue engineering is vital in bridging this gap. By
combining scaffolds, cells, and biochemical and physical stimuli, we can elucidate early
alterations in DCMP, as well as test potential therapies for treatment.
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CHAPTER 2: RESEARCH MOTIVATION, SPECIFIC AIMS AND PROJECT
SIGNIFICANCE
2.1 Introduction
As diabetes mellitus rises to epidemic proportions across the world, so follows
an upsurge in the number of patients who have heightened risk of cardiovascular disease.
The risk of cardiovascular disease, such as hypertension, diabetic cardiomyopathy, and
atherosclerosis are increased in diabetic patients.1,2 Diabetic cardiomyopathy (DCMP)
is a ventricular dysfunction that specifically occurs in diabetic patients independent of
coronary artery disease, hypertension or valvular abnormalities.3
Heart transplantation is the only cure for DCMP, which has a very long wait list.4
Treatment is lumped in with other cardiomyopathies and heart failure, however these
therapies only treat the symptoms and downstream complications that accompany heart
failure without addressing the roots of the problem.5 Understanding the fundamental
mechanisms in the early stages of DCMP are vital for early diagnosis and targeted
therapies. As of now, comprehension of this disease has depended on rodent models, cell
culture models, and cadaveric human patient hearts.6,7 Human DCMP cadaveric hearts
have been useful for elucidating end stage cellular and extracellular changes and rodent
and cell culture models have been utilized to fill in the gaps. However there are many
discrepancies that exist between humans and rodents.8–10 Human cells have been
employed to examine specific cell type alterations associated with the diabetic
environment, but this is in an oversimplified 2D static environment, lacking an
extracellular matrix (ECM).11
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Our long-term goal is to develop a tissue engineering platform to investigate
mechanisms of early cellular and extracellular alterations of DCMP. To achieve this goal,
we will examine known hallmarks of DCMP in two tissue-engineered models developed
in our lab. This will be accomplished by containing tissue-engineered myocardium made
by combining human cardiomyocytes and decellularized porcine myocardium in (1) a 3D
Kube minibioreactor or (2) an in-house electromechanical bioreactor cultured in a high
glucose environment.
Preliminary studies in our lab have shown cellular and extracellular alterations
associated with DCMP in rat cardiomyocytes cultured in 3D Kube minibioreactors for 14
days in high glucose. Within our lab we have also developed a physiologically relevant
myocardial electromechanical bioreactor. With these encouraging results we chose to
move forward and examine early human cardiomyocytes (hCM) modifications in the 3D
Kube minibioreactor, as well as our electromechanical bioreactor in a simulated
“diabetic” environment with additional glucose. We hypothesize that by creating and
utilizing tissue engineering platforms for modelling DCMP we can elucidate early
alterations in hCM and the ECM to determine points for diagnosis and treatment.
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2.2 Specific Aims
Aim 1: Ascertain if tools and methods we employ are suitable for analysis and
highlight DCMP alterations (Presented in Chapter 3)
Hypothesis: Methods utilized will detect alterations in the ECM and cells of the heart
caused by hyperglycemia and dyslipidemia in the diabetic environment
Approach: Hearts from normal and diabetic (streptozotocin type I induced) rats will be
harvested and analyzed for this study 8 weeks after induction. Diabetic and DCMP
cellular and ECM changes will be assessed via histological staining, western blotting, and
specific assays. Alterations such as lipid accumulation, endogenous antioxidant
mechanisms, advanced glycation endproduct (AGE) buildup, matrix metalloproteinase
(MMP) activity, apoptosis, autophagy, endoplasmic reticulum (ER) stress, and
perivascular and interstitial fibrosis.

Aim 2: Assess suitability of human cardiomyocytes for the creation of a threedimensional (3D), dynamic in vitro model of DCMP (Presented in Chapter 4)
Hypothesis: hCMs will be modified and respond in a hyperglycemic milieu
Approach: Progenitor hCM will be cultured for two weeks in a high glucose
environment (4.5g/L glucose) and compared to hCM cultured in normal glucose (1g/L
glucose). Immunofluorescence, western blotting, and specialized kits and assays will be
used to analyze the two groups. Cells will be analyzed for alterations such as lipid
accumulation, lipid peroxidation, reactive oxygen species (ROS) generation, endogenous
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antioxidant mechanisms, AGE buildup, receptor for AGE (RAGE) expression, MMP
activity, apoptosis, autophagy, and ER stress.

Aim 3: Develop a myocardial-like tissue platform using proper biochemical,
mechanical, and electrical cues (Presented in Chapter 5)
Hypothesis: Applying specific mechanical, electrical, and biochemical stimuli,
cardiomyocytes seeded on scaffolds will mimic the organization and function of
myocardial tissues
Approach: hCM from Aim 2 will be seeded into decellularized porcine myocardium and
exposed to mechanical and electrical stimuli for 14 days via a modified Flexcell
bioreactor to induce cell organization. Static controls will be cultured in tandem. Cell
viability, as well as the presence of specific cardiac cell markers, such as connexin 43,
sarcomeric α-actinin, desmin, and GATA-4 will be assessed. The extracellular matrix
will also be analyzed for changes in collagen IV and laminin expression.

Aim 4: Investigate cardiac cell and matrix modifications induced by oxidative stress
in diabetic environment (Presented in Chapter 6)
Hypothesis: High glucoxidative environments induce pathological modifications in cells
and extracellular matrix
Approach: Lipid accumulation, endogenous antioxidant mechanisms, AGE accrual,
MMP activity, apoptosis, autophagy, and ER stress will be assessed after the myocardiallike tissue is exposed to physiological-like conditions in vitro in either normal (1 g/L) or
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high (4.5 g/L) glucose. Two bioreactor platforms will be tested for 14 days: (1) a 3D
Kube perfusion minibioreactor and (2) an electromechanical bioreactor developed in our
lab (from Aim 3).

2.3 Significance of Proposed Project
This project is expected to have a significant impact by bridging an existing gap
in the understanding of early alterations of human cardiac cells and the extracellular
matrix in DCMP and the diabetic environment with tissue engineering. Development of
an organotypic, highly reproducible, systematic model will allow for strides to be made
not only in the clarification of DCMP, diagnosis, and patient-tailored options for
treatment and prevention, but in validating therapies and understanding the progression of
DCMP.
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CHAPTER 3: CHARACTERIZATION OF AN IN VIVO DIABETIC CARDIAC
DISEASE MODEL
3.1 Introduction
The only cure for DCMP is a whole heart transplant.4 There is no specific marker
for this cardiomyopathy and it is diagnosed after symptom manifestation, including but
not limited to, shortness of breath, fatigue, chest pain, and fluid retention.5 As of now,
treatment of DCMP is the same as other cardiomyopathies, with a focus on blood glucose
control.2 DCMP is a complex disease and understanding its progression is the key to
determining distinct markers for early diagnosis, as well as targeted treatments.
Animal models have been widely utilized to understand the underlying
mechanisms of DCMP and cardiac alterations associated with diabetes.6 One of these
popular models is the streptozotocin (STZ) type I diabetic rat model. This type I diabetic
rat model is produced through tail vein injection of STZ, a glucosamine-nitrosourea
antibiotic that causes beta cell necrosis, leading to insulin deficiency.7 STZ is favorably
up taken by beta cell GLUT2 glucose transporters in the pancreas as it has a similar
structure to glucose.7 This diabetic rat model has been shown to exhibit decreased
glucose utilization, increased FFA oxidation, decreased mitochondrial function, impaired
calcium handling, and increased oxidative stress.6
We hypothesized that by utilizing this diabetic STZ rat model, we could detect
alterations in the ECM and cells of the heart caused by hyperglycemia and dyslipidemia
in the diabetic environment.

64

3.2 Materials and Methods
3.2.1 Materials
Streptozotocin was obtained from Sigma (S0130). Insulin used was Humulin N
U-100 NPH from Lilly (Indianapolis, IN). AlphaTRAK® (GenII) test strip and the
AlphaTRAK® Blood Glucose Monitoring System were from Abbot Laboratories,
Animal Health (Abbott Park, IL). Bicinchoninic acid protein assay was from Pierce
Biotech (Rockford, IL). Electrophoresis apparatus, gel imager and imaging software,
chemicals, and molecular weight standards were from Bio-rad (Hercules, CA). BM
Chemiluminescence Western Blotting kit (Mouse/ Rabbit) was obtained from Roche
(Indianapolis, IN). The Vectastain Elite kit, ABC diaminobenzidine tetrahydrochlorine
peroxidase substrate kit, and Vectashield mounting medium were from Vector
Laboratories (Burlingame, CA). The following antibodies were used: rabbit antisuperoxide dismutase-2 (Abcam, ab13534), rabbit anti-advanced glycation endproducts
(Abcam, ab23722), rabbit anti-protein kinase RNA-like endoplasmic reticulum kinase
(Abcam, ab192591), rabbit anti-alpha-smooth muscle actin (Abcam, ab5694), rabbit anticaspase-3 (Millipore, 06-735). Biotinylated anti-rabbit IgG was purchased from Vector
Laboratories (Burlingame, CA). Movat’s Pentachrome Kit was from Poly Scientific (Bay
Shore, NY). All other chemicals were of the highest purity and purchased from SigmaAldrich Corporation (Lakewood, NJ).
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3.2.2 Rat Streptozotocin-Induced Diabetes Model
Diabetic rat models were produced utilizing adult male Sprague-Dawley rats
(n=20, weight 300-350g) after tail vein injection of a single dose of sterile filtered
55mg/kg streptozotocin (STZ) solution in 0.1M citrate buffer (pH 5). Control rats were
given an equal volume of sterile citrate buffer (n=20). 3 days after diabetic induction,
AlphaTRAK® (GenII) strips with the AlphaTRAK® Blood Glucose Monitoring System
were used to measure levels of blood glucose 3-4 times a day. Diabetic rats were given
subcutaneous injections of long-lasting insulin (2-4U Isophane) every other day after the
establishment of diabetes (>400mg glucose/dL blood). This ensured blood glucose levels
were maintained at reasonable ranges (400-600mg glucose/dL blood) and would prevent
weight loss and ketonuria development. Adequate health parameters were maintained by
closely monitoring glucose levels, individual weights, hydration status, and food and
water consumption. Godley-Snell Research Center Animal Facility associated staff and
attending university veterinarian provided food and water for the animals ad libitum, as
well as animal care. 8 weeks after STZ or control injection, rats were humanely
euthanized by carbon dioxide and hearts were harvested. Hearts for protein extraction
were flash frozen in liquid nitrogen, transported on dry ice for storage at -20°C. For
histological analysis, hearts were either fixed in 10% formalin before processing or
embedded and frozen in optimal cutting temperature (OCT) compound. National Institute
of Health (NIH) guidelines for the care and use of laboratory animals (NIH publication
#86-23 Rev. 1996) were observed. The Animal Research Committee at Clemson
University approved the animal protocol for this experiment.
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3.2.3 Histological Analysis
Rat hearts were dissected into 4 coronal sections before paraffin processing and
embedding, for more in-depth histological analysis. Movat’s pentachrome staining was
utilized to compare morphology between the normal and diabetic hearts (n=3 for each
group). Rehydrated paraffin sections (5um) were stained using a Movat’s pentachrome
kit. Manufacturer’s guidelines were followed.
Immunohistochemistry (IHC) was performed for detection of superoxide
dismutase-2 (SOD-2), advanced glycation endproducts (AGE), and alpha-smooth muscle
actin (α-SMactin) to compare diabetic and normal rat hearts (n=3 for each group).
Briefly, antigen retrieval was performed on rehydrated paraffin sections (5um) with
heated (90-100 degrees C, 10 min) 10mM citric acid (pH=7.4). Slides were
permeabilized with 0.025% Triton X-100 for 5 minutes and then incubated in normal
blocking serum for 45 minutes. Primary antibodies (rabbit anti-SOD-2 10ug/mL dilution,
rabbit anti-AGE 4ug/mL dilution, or rabbit anti-a-SMactin 1ug/mL dilution) were
incubated overnight at 4 degrees Celsius. Negative controls were obtained by omitting
the primary antibody. Endogenous peroxidases were blocked with 0.3% hydrogen
peroxide in 0.3% normal horse serum for 30 minutes. The secondary biotinylated antirabbit antibody was applied for 30 minutes. Antibody staining was visualized using the
Vector ABC peroxidase substrate kit and then lightly counterstained with diluted
hematoxylin, before mounting. A Zeiss Axiovert 40CFL microscope with AxioVision
Release 4.6.3 digital imaging software (Carl Zeiss MicroImaging, Inc. Thornwood, NY)
was utilized to obtain images.
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3.2.4 Lipid Staining
Lipid accumulation was visualized via oil red O or sudan black staining on
cryosectioned rat hearts (n=3 per group) and mounted with aqueous Vectashield
mounting medium. Light images were taken on a Zeiss Axiovert 40CFL microscope, as
described before. For oil red o, slides were fixed in 4% paraformaldehyde, rinsed in
distilled, deionized water (ddH2O), rinsed in 60% isopropanol, and stained in 0.3% Oil
Red O in isopropanol solution. Slides were then rinsed twice in 60% isopropanol, stained
in a 1 to 1 hematoxylin in ddH2O solution, and rinsed in ddH2O.
For sudan black staining, were fixed in 4% paraformaldehyde, rinsed in ddH2O,
rinsed in 35% ethanol, followed by 70% ethanol, and stained in sudan black in 70%
ethanol. Slides were rinsed twice in 70% ethanol, followed by a rinse in tap water, stained
in a 1 to 1 hematoxylin in ddH2O, and rinsed in ddH2O.
3.2.5 Detection of Caspase-3, SOD-2, AGE, and PERK
Western blotting was employed to compare amounts of caspase-3, SOD-2, AGE,
and protein kinase RNA-like endoplasmic reticulum kinase (PERK) between the diabetic
(n=5) and normal (n=4) rat hearts. Proteins were extracted by pulverizing liquid nitrogenfrozen tissue samples from the left ventricular wall and homogenizing them in
radioimmunoprecipitation assay (RIPA) extraction buffer (50mM Tris-HCl pH 7.4,
150mM sodium chloride (NaCl), 1mM ethylenediaminetetraacetic acid (EDTA), 1%
Triton X-100, 1% Sodium Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), with
protease inhibitor cocktail). Protein concentrations in the samples were found using a
bicinchoninic acid protein (BCA) assay. For each sample, 20ug of protein per lane was
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loaded and a pre-stained molecular weight standard was loaded in one of the lanes.
Protein from the gels were transferred to polyvinylidine fluoride membranes. Primary
antibodies (rabbit anti-AGE 0.5ug/mL dilution, rabbit anti-SOD-2 1ug/mL dilution,
rabbit anti-caspase-3 1ug/mL dilution, or rabbit anti-PERK 1ug/mL dilution) were
applied overnight at 4 degrees C. The secondary antibody from the anti-mouse/rabbit kit
was then applied for 45 minutes at room temperature. The polyvinylidine fluoride
membranes were fluorescently tagged with detection solution from the anti-mouse/rabbit
kit and then imaged using the Chemi-Doc™ XRS+ system from Bio-rad (Hercules, CA).
Relative band intensities were determined using Bio-rad Image Lab Software Version
5.1, beta build 1.
Relative amounts of caspase-3 within the rat hearts (n=3 per group) were
determined with the Caspase-3 Fluorogenic Spectroscopic Assay from BD Pharmingen
(San Jose, CA). Manufacturer’s protocol was followed. Intensities were measured using
the Synergy H1 Hybrid Reader System from BioTek (Winooski, VT).
3.2.6 Matrix Metalloproteinase Activity Analysis
Protein extracts from hearts were extracted using the RIPA buffer method
(above). Protein concentrations in the samples were found using a BCA assay. For each
sample, 20ug of protein per lane were loaded into a gelatin zymography gel (n=2 per
group), as was a pre-stained molecular weight standard into a separate lane. After
electrophoresis separation, the zymography gel was washed in a triton-X solution and
matrix metalloproteinases (MMPs) were activated with a brij-35 development buffer for
24 hours at 37 degrees C. After staining with Coomassie, MMP clear bands were imaged
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using the Chemi-Doc™ XRS+ system and evaluated by densitometry using the using
Bio-rad Image Lab Software.
3.2.7 Glutathione Detection
Protein extracts were taken from rat hearts using the RIPA buffer extraction
method (above). Protein concentrations in the samples were found using a BCA assay.
Glutathione was detected in rat hearts (n=3 per group) using Cell Technology’s
fluorescent thiol detection kit assay (Mountain View, CA). Manufacturer protocol was
utilized. Intensities were measured the Synergy H1 Hybrid Reader System.
3.2.8 Statistical Analysis
Results are expressed at mean ± standard deviation (SD). Statistical analysis was
performed between groups utilizing Welch’s two-tailed t-test in excel. Significance was
determined with an alpha (α) value of 0.05.
3.3 Results
3.3.1 Extracellular Matrix Analysis
Analysis of normal and diabetic rat hearts was performed to determine if ECM
changes associated with DCMP were noticeable. On the macro scale, diabetic hearts
markedly enlarged and dilated when compared to normal rat hearts (Figure 3.1). As seen
in Figure 3.2, diabetic rat hearts had higher instances of fibrosis within the myocardium
of the left ventricle and blood vessels, as revealed by Movat’s pentachrome staining and
IHC staining of α-SMactin. Analysis of MMPs revealed reduced activity in diabetic rat
hearts (Figure 3.3).
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Figure 3.1: Harvested diabetic (bottom) and normal (top) rat hearts.
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Figure 3.2: Extracellular matrix (ECM) analysis of normal and diabetic rat hearts.
Movat’s pentachrome staining (top and middle) of the left ventricle and blood vessels
(black=nuclei or elastic fibers, yellow=collagen or reticular fibers, blue=ground
substance or mucin, bright red=fibrin, red=muscle) in hearts. Immunohistochemistry
(IHC) staining

(bottom) was

used

for α-smooth

muscle actin

(α-SMactin,

brown=positive, dark purple=nuclei) visualization. Negative controls not shown for IHC.
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Figure 3.3: Matrix metalloproteinase (MMP) activity assessment in rat hearts. Gelatin
zymography was used to determine MMP activity in diabetic and normal rat hearts.
RDU= relative densitometry units.

73

Figure 3.4: Advanced glycation endproducts (AGE) formation within normal and
diabetic rat hearts. (A) Hearts were stained for AGEs via immunohistochemistry (IHC)
(brown=positive, dark purple=nuclei). (B) AGEs in hearts were analyzed with western
blotting. RDU= relative densitometry units.
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Figure 3.5: Lipid accumulation staining in diabetic and normal rat hearts. Lipids in
hearts were visualized with oil red O (red=lipids) and sudan black (black=lipids) staining.

Figure 3.6: Investigation of apoptosis in rat hearts. Relative expression of caspase-3, an
apoptosis marker, was measured with (A) a caspase-3 assay and (B) western blotting. *
indicates statistical significance. RDU=relative densitometry units.
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3.3.2 AGE Formation, Lipid Accumulation, and Apoptosis
As hyperglycemia and hyperlipidemia are hallmarks of DM and DCMP, we
sought to compare diabetic rat hearts to normal rat hearts for glycoxidation and lipid
accumulation. As shown in Figure 3.4, AGEs were present in both normal and diabetic
rat heart tissue, as seen in IHC AGE staining. Western blot protein analysis of AGEs
showed no significant difference between normal and diabetic rat hearts. AGE staining of
blood vessels of the hearts demonstrated increased circulating AGEs in diabetic rat
hearts. Staining of lipids via oil red O and sudan black, displayed higher lipid
accumulation within the diabetic rat heart tissue (Figure 3.5). Hyperglycemia and
hyperlipidemia can both lead to programmed cell death, known as apoptosis. Caspase-3,
a marker of apoptosis, was used to investigate this. It was found via western blotting and
a specific caspase-3 assay that caspase-3 expression was significantly increased, and
therefore apoptosis, in diabetic rat hearts compared to normal rat hearts (Figure 3.6).
3.3.3 Antioxidant Defense Mechanisms and Endoplasmic Reticulum Stress
One element of DCMP is oxidative stress caused by an imbalance between
reactive oxygen species (ROS) and antioxidant defense mechanisms, such as SOD-2 and
glutathione. As observed in Figure 3.7, there was a significant reduction in SOD-2 and
glutathione expression in diabetic rat hearts. IHC revealed normal rat hearts to have
SOD-2 expressed throughout the tissue, while SOD-2 expression in diabetic rat hearts
were concentrated in the myocardium. Western blot protein detection showed SOD-2 was
significantly decreased in diabetic rat hearts. Glutathione content in diabetic rat hearts
was also significantly decreased as measured by a glutathione assay.
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Figure 3.7: Antioxidant defense mechanisms utilized by normal and diabetic rat hearts.
Superoxide dismutase-2 (SOD-2) was visualized with immunohistochemistry (IHC) (top)
(brown=positive, dark purple=nuclei) and detected with western blotting (bottom left);
results are in relative densitometry units (RDU). Glutathione was measured via an assay
(bottom right).
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Another trait of diabetes and DCMP is ER stress within cells due to buildup of
misfolded proteins. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) is
upregulated in ER stress and its pathway triggers the unfolded protein response. Western
blotting of this protein showed an upward trend in diabetic rat hearts.

Figure 3.8: Endoplasmic reticulum (ER) stress in normal and diabetic rat hearts. Protein
kinase RNA-like endoplasmic reticulum kinase (PERK), a marker for ER stress, was
detected by western blotting. RDU= relative densitometry units.
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3.4 Discussion
Experimental

animal

models

have

been

employed

for

understanding

cardiovascular alterations associated with diabetes, specifically DCMP. Known hallmarks
of this disease at the cellular and extracellular levels, include fibrosis, buildup of AGEs,
lipid accumulation, oxidative stress, ER stress, apoptosis, and autophagy.8 In this study
we sought to use a diabetic rat model to see if there were noticeable ECM and cellular
alterations in the hearts associated with DCMP. We also wanted to optimize the tools and
methods we were using in investigating and perceiving these changes.
The STZ diabetic type 1 model used for this study provided a baseline, as it has
been thoroughly studied in literature and diabetic rat hearts from this experimental model
have been shown to display alterations and characteristics of DCMP.6 STZ is a popular
diabetic rodent model as it is easily administered to the animal and takes less time to
produce than genetic diabetic rodent models.7 This model can also be combined with
genetically altered rodents, making it favorable for specific research into genetic
disorders combined with diabetes, exacerbated diabetic models, and knock out models.9,10
While this is a popular experimental model, there are disadvantages that have been noted
with intravenous STZ administration to create this diabetic state. One of the most
significant is systemic genotoxic effects from the injected STZ.11 Kume et. al. reported
that there are changes in hepatic gene expression, such as downregulation of genes
associated with lipid metabolism and glucose as soon as 48 hours after STZ
administration. These modifications occurred before a rise in blood glucose levels,
implying that genes unrelated to hyperglycemia might be altered.12 It has also been
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suggested that through a p38 mitogen-activated protein kinase-dependent oxidative stress
mechanism STZ reduces cardiac function.13 Problems can also arise within this model, as
the intensity of diabetes developed within STZ treated rats can differ, explicitly seen in
lack of mitochondrial dysfunction in STZ diabetic rats without ketosis.14
Within rat hearts that were treated with STZ and diabetic for 8 weeks, there were
noticeable changes to the ECM as reported before, such as fibrosis.15,16 Upon
observation, diabetic rat hearts were increased in size and dilated when compared to
normal hearts. Interstitial fibrosis was noticeably spread through the endocardium and
myocardium of left ventricle of diabetic rat hearts, whereas it was not in normal rat
hearts. Perivascular fibrosis within the diabetic myocardium was also noticed with an
increased amount of collagen and thickened walls. This could be due to an imbalance
between collagen production and degradation, as MMP activity was also lowered in
diabetic hearts. The diabetic condition is a prolonged, highly inflammatory state and
inflammation

activates

increased

collagen

production

through

myofibroblast

activation.17,18
As the hyperglycemia and dyslipidemia are traits of a diabetic environment, we
investigated glycoxidation, specifically the presence of AGEs, and lipid accumulation
within the rat heart tissue.19,20 We found there was no significant difference in AGE
expression within the tissue of normal and diabetic hearts, however AGEs circulating
within diabetic blood vessels was visibly higher as seen in staining. AGEs are naturally
occurring within tissue.19 8 weeks may have been too short of a time for AGEs to become
overexpressed in the diabetic heart tissue and longer timepoints may be needed to see
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over accumulation of AGEs in the tissue. Also, the AGE marker utilized for this study is
a pan AGE marker. Other specific AGE markers, such as carboxymethyl lysine, could
show significant differences between the hearts.21 Diabetic hearts had noticeably
increased lipid accumulation when compared to normal hearts. This has also been noted
in literature.22,23
Programmed cellular death or apoptosis is another hallmark of DCMP. Metabolic
changes, such as FFA usage and oxidative stress, lead to apoptosis. Caspase-3, an
apoptosis marker, was significantly increased in diabetic rat hearts. Apoptosis has been
shown to be increased in the STZ diabetic rat hearts.24,25
As oxidative stress is increased in the diabetic environment, we examined
antioxidant defense mechanisms to determine if there were differences between the
hearts.26 SOD-2 and glutathione, endogenous cellular antioxidants, were investigated.27
SOD-2 expression was sequestered in the myocardium of diabetic rat hearts, while SOD2 was homogenously throughout normal hearts. SOD-2 and glutathione were both
significantly reduced in diabetic rat hearts, illustrating that antioxidant defense
mechanisms within these hearts are either hindered within the diabetic environment or
have been depleted through excessive utilization.
ER stress has also been shown to be increased in the diabetic environment due to
misfolded or unfolded proteins within the ER.28 In this state, PERK is activated and
triggers the unfolded protein response (UPR) pathway to control protein quality.29 In
diabetic rat hearts it was found that there was an upward trend of PERK, showing that ER
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stress was slightly higher in diabetic rat hearts. This is however, one of three major
pathways that can be activated and one facet of the story.
3.5 Conclusions
STZ type 1 diabetic rat models are useful for investigating ECM and cellular
changes associated with DCMP in vivo, however there are discrepancies within the
severity of diabetes in this model and systemic STZ administration does not allow for a
full recapitulation diabetes seen in human patients. The tools and methods we employed
in this diabetic rat heart study are suitable for analysis and highlighted DCMP alterations.
These techniques will be useful for future studies into this disease.
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CHAPTER 4: ASSESMENT OF A 2D IN VITRO HUMAN CARDIOMYOCYTE
DIABETIC CARDIAC MODEL
4.1 Introduction
Cardiomyocyte (CM) adaptations in response to the diabetic environment are of
interest in the beginning stages of diabetic cardiomyopathy (DCMP). CMs are
responsible for contraction of the myocardium and when they are compromised, so is
overall functionality of the heart.1 Hyperglycemia and dyslipidemia in the diabetic
milieu, lead to a loss of metabolic flexibility within the cell.2 Free fatty acids are
preferentially used as an energy source, followed by lipid accumulation and peroxidation,
with the over formation of reactive oxygen species (ROS).3 ROS is produced faster than
the cell can eliminate it through endogenous antioxidant defenses, causing oxidative
stress.4,5 Cellular autophagy and apoptosis follow prolonged oxidative stress.6,7 Within
this diabetic climate, advanced glycation endproducts (AGEs) aggregate, forming
irreversibe crosslinks, with a decrease in matrix metalloproteinase (MMP) activity.8 This
imbalance gives rise to tissue fibrosis. CMs become hypertrophic as they must work that
much harder to maintain efficiency to compensate for CM loss and tissue stiffening.9
Overtime, this can lead to heart failure.
To understand CM modifications in the diabetic environment, two-dimensional
(2D) cell culture of this cell type has been employed with the addition of glucose to the
cell culture media. Cells such as neonatal rat CMs, induced pluripotent stem cells
(iPSCs), progenitor CMs, immortalized CMs, and embryonic stem cells (ESCs) have
been utilized for these studies and have shown to be altered under these conditions.10–15
We chose to investigate human progenitor CMs (hCMs) as they are commercially

85

available, able to expand in culture, adult human cells, and there were no ethical concerns
attached, as there are with ESCs.16 We hypothesized that we would see alterations and
responses in these hCMs known in the diabetic state by culturing them with additional
glucose. The goal of this initial study was to determine if these cells would be suitable for
the creation of a three-dimensional (3D), dynamic in vitro model of DCMP.
4.2 Materials and Methods
4.2.1 Materials
Progenitor human cardiac myocytes (hCM) were from Promocell GmbH
(Heidelberg, Germany). Dulbecco’s Modified Eagle Medium (DMEM) and antibiotic /
antimycotic were from Corning Incorporated (Oneonta, NY). Fetal Bovine Serum (FBS)
was from Atlanta Biologicals (Atlanta, GA). Bicinchoninic acid protein assay was from
Pierce Biotech (Rockford, IL). Electrophoresis apparatus, gel imager and imaging
software, chemicals, and molecular weight standards were from Bio-rad (Hercules, CA).
BM Chemiluminescence Western Blotting kit (Mouse/ Rabbit) was obtained from Roche
(Indianapolis, IN). Paraformaldehyde was from Electron Microscopy Sciences (Hartfield,
PA). Triton X-100 was from Alfa Aesar (Ward Hill, MA). Bovine Serum Albumin was
from Rockland Immunochemicals Inc. (Limerick, PA). The following antibodies were
used: rabbit anti-superoxide dismutase-2 (Abcam, ab13534), rabbit anti-caspase-3
(Millipore, 06-735 or Abcam, ab32042), rabbit anti-receptor for advanced glycation
endproducts (Abcam, ab37647), mouse anti-N-epsilon-(carboxylmethyl)lysine (R&D
Systems, MAB3247), rabbit anti-light chain 3B (Abcam, ab48394), and rabbit antiprotein kinase RNA-like endoplasmic reticulum kinase (Abcam, ab192591). Alexa
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Fluor® fluorescent secondary antibodies (mouse and rabbit) were purchased from
Molecular Probes (Eugene, OR). All other chemicals were of the highest purity and
purchased from Sigma-Aldrich Corporation (Lakewood, NJ).
4.2.2 Culture of Human Cardiomyocytes
Progenitor human cardiac myocytes (hCMs) were cultured for 14 days in normal
glucose and high glucose media. Normal and diabetic media constituted of Dulbecco’s
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1%
antibiotic/antimycotic (penicillin-streptomycin), with 5mM (1g/L) and 25mM (4.5g/L)
glucose, respectively.
4.2.3 Immunofluorescence for Caspase-3, SOD-2 and CML/RAGE
Immunofluorescence was used for the visualization of caspase-3, superoxide
dismutase 2 (SOD-2,) and carboxymethyl lysine/receptor for advanced glycation
endproduct (CML/RAGE) in normal and high glucose conditioned hCMs. Cells were
fixed with 4% warm paraformaldehyde for 20 minutes and then permeabilized with 0.2%
Triton X-100 (10 minutes) at room temperature. A blocking solution of 5% bovine serum
albumin and 0.05% Triton X-100 was then applied for 45 minutes. Cells were incubated
in primary antibodies (rabbit anti-caspase-3 Abcam 1ug/mL, rabbit anti-SOD-2 at
4ug/mL, or mouse anti-CML at 1ug/mL and rabbit anti-RAGE at 1ug/mL) in a 1 to 1
mixture of blocking solution to phosphate buffered saline for 2 hours. For negative
controls, a 1 to 1 solution of blocking solution to phosphate buffered saline was used,
without primary antibodies. Alexa Fluor® fluorescent secondary antibodies (anti-rabbit
or anti-mouse) were applied for 1 hour at room temperature. Cell nuclei were stained
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with 4’,6-diamidino-2-phenylindole (DAPI) and a Zeiss Axiovert 40CFL microscope
with AxioVision Release 4.6.3 digital imaging software, UV light box, and filter from
Carl

Zeiss

MicroImaging,

Inc.

(Thornwood,

NY),

was

utilized

to

obtain

immunofluorescence images.
4.2.4 Detection of Caspase-3, SOD-2, CML, and LC3B
Western blotting was employed to compare amounts of caspase-3, SOD-2, CML,
light chain 3B (LC3B), and protein kinase RNA-like endoplasmic reticulum kinase
(PERK) between normal glucose (n=3,4,4,4,4 respectively) and high glucose (n=3,4,4,5,3
respectively) conditions. Proteins were extracted by radioimmunoprecipitation assay
(RIPA) extraction buffer (50mM Tris-HCl pH 7.4, 150mM sodium chloride (NaCl),
1mM ethylenediaminetetraacetic acid (EDTA), 1% Triton X-100, 1% Sodium
Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), with protease inhibitor cocktail).
Protein concentrations in the samples were found using a bicinchoninic acid protein
(BCA) assay. For each sample, 20ug of protein per lane was loaded and a pre-stained
molecular weight standard was loaded in one of the lanes. Protein from the gels were
transferred to polyvinylidine fluoride membranes. Primary antibodies (rabbit anticaspase-3 Millipore 1ug/mL, rabbit anti-SOD-2 1ug/mL, mouse anti-CML 1ug/mL,
rabbit anti-LC3B 1ug/mL, or rabbit anti-PERK 1ug/mL) were applied overnight at 4°C.
The secondary antibody from the anti-mouse/rabbit kit was then applied for 45 minutes at
room temperature. The polyvinylidine fluoride membranes were fluorescently tagged
with detection solution from the anti-mouse/rabbit kit (1 minute) and then imaged using
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the Chemi-Doc™ XRS+ system from Bio-rad (Hercules, CA). Relative band intensities
were determined using Bio-rad Image Lab Software Version 5.1, beta build 1.
Relative amounts of caspase-3 within cell cultures were examined with the
ApoTarget Caspase-3 / CPP32 Colorimetric Protease Assay from Invitrogen (Carlsbad,
CA). Manufacturer’s protocol was followed. Total protein was measured via a BCA
assay and 100ug was used per sample (n=2 per group). Intensities were measured using
the Synergy H1 Hybrid Reader System from BioTek (Winooski, VT).
4.2.5 Matrix Metalloproteinase Activity Analysis
Protein extracts from hCMs were taken from normal (n=4) and high (n=4)
glucose groups using the RIPA buffer extraction method (above). Protein concentrations
in the samples were found using a BCA assay. For each sample, 20ug of protein per lane
were loaded into a gelatin zymography gel, as was a pre-stained molecular weight
standard into a separate lane. After electrophoresis separation, the zymography gel was
washed in a triton-X solution and matrix metalloproteinases (MMPs) were activated with
a brij-35 development buffer for 24 hours at 37 degrees C. After staining with
Coomassie, MMP clear bands were imaged using the Chemi-Doc™ XRS+ system and
evaluated by densitometry using the using Bio-rad Image Lab Software.
4.2.6 Lipid Accumulation and Peroxidation Staining
Intracellular lipid accumulation was visualized via Oil Red O staining. Briefly,
cells were fixed in 4% paraformaldehyde, rinsed in distilled deionized water (ddH2O),
rinsed in 60% isopropanol, and stained in 0.3% Oil Red O in isopropanol solution. Cells
were then rinsed twice in 60% isopropanol, stained in a 1 to 1 hematoxylin to ddH2O
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solution, and rinsed in ddH2O. Light images were taken on a Zeiss Axiovert 40CFL
microscope with AxioVision Release 4.6.3 digital imaging software from Carl Zeiss
MicroImaging, Inc. (Thornwood, NY).
Lipid peroxidation was investigated in normal and high glucose hCM cultures by
employing the Click-iT® Lipid Peroxidation Detection with Linoleamide Alkyne Kit
from Molecular Probes (Eugene, OR). Manufacturer protocol was utilized. Cells nuclei
were stained with DAPI and imaged via the immunofluorescence protocol previously
discussed (above).
4.2.7 Reactive Oxygen Species Generation Analysis
Reactive oxygen species (ROS) generation in normal and high glucose hCM
cultures were determined by utilizing the CellROX® Oxidative Stress Reagents Kit from
Molecular Probes (Eugene, OR). Manufacturer protocol was utilized. Cell nuclei were
stained with DAPI and imaged using immunofluorescence protocol mentioned previously
(above).
4.2.8 Autophagy Inspection
Autophagy in normal and high glucose conditioned hCMs was studied by
utilizing the LC3B Antibody Kit for Autophagy from Invitrogen (Carlsbad, CA).
Manufacturer protocol was utilized. Cell nuclei were stained with DAPI and
immunofluorescence images were captured as discussed before (above).
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4.2.9 Statistical Inquiry
Results are expressed at mean ± standard deviation (SD). Statistical analysis was
performed between groups utilizing Welch’s two-tailed t-test in excel. Significance was
determined with an alpha (α) value of 0.05.
4.3 Results
4.3.1 Advanced Glycation Endproducts and Matrix Metalloproteinase Activity
Analysis of in vitro 2D hCM cultures after two weeks in normal or high glucose
was performed to determine if there were noticeable changes in expression of advanced
glycation endproducts (AGEs) with their receptor (RAGE) and matrix metalloproteinase
(MMP) activity. Immunofluorescence images of carboxymethyl lysine (CML), an AGE,
and RAGE, showed greater expression of both in high glucose hCM cultures when
compared to hCM cultured in normal glucose (Figure 4.2). Based on western blotting,
CML illustrated an upward trend in high glucose hCM treated cells. There was a
downward trend in MMP activity in high glucose cultured hCM as revealed by gelatin
zymography of protein lysates (Figure 4.1).
4.3.2 Lipotoxicity and Reactive Oxygen Species Formation
Determination of lipotoxicity and reactive oxygen species (ROS) in normal and
high glucose hCM cultures was executed with oil red O lipid staining and specialized kits
for lipid peroxidation and ROS detection. By using the Click-iT® Lipid Peroxidation
Detection with Linoleamide Alkyne Kit, we were able to observe increased lipid
peroxidation within hCM cultured in high glucose (Figure 4.3). hCM cultured in high
glucose also showed higher lipid accumulation as visualized by oil red O lipid staining.
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ROS aggregation was examined with the CellROX® Oxidative Stress Reagents Kit. It
was noticed that high glucose hCM had more formation of ROS, than normal glucose
hCM.

Figure 4.1: Matrix metalloproteinase (MMP) activity analysis. Gelatin zymography was
used to compare MMP activity in high and normal glucose hCM conditions.
RDU=relative densitometry units.
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Figure 4.2: Advanced glycation endproducts and their receptor in hCM high and normal
glucose cell culture. (A) Immunofluorescence staining for an advanced glycation
endproduct, carboxymethyl lysine (CML, green), receptor for advanced glycation
endproducts (RAGE, red), and staining with 4’,6-diamidino-2-phenylindole (DAPI) for
nuclei (blue) in hCM cell cultures. Negative controls not shown. (B) Western blotting for
CML in hCM cultures. RDU=relative densitometry units.
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Figure 4.3: Lipotoxicity and reactive oxygen species formation in hCM culture. Lipid
peroxidation staining (green) of hCM in normal and high glucose conditions with ClickiT® Lipid Peroxidation Detection with Linoleamide Alkyne Kit and nuclei staining
(blue) with DAPI (top). Oil red O lipid staining (red) in hCM culture (middle) with cell
hematoxylin staining (purple). Reactive oxygen species (ROS) visualization (green) in
hCM culture with CellROX® Oxidative Stress Reagents Kit and DAPI nuclei staining
(blue).
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4.3.3 Endoplasmic Reticulum Stress and Superoxide Dismutase-2 Antioxidant Defense
Endoplasmic reticulum stress was analyzed with a marker, protein kinase RNAlike endoplasmic reticulum kinase (PERK). Western blotting detection showed no
statistical difference between groups (Figure 4.4). Endogenous antioxidant defenses
against ROS were assessed in normal and high glucose conditioned hCM by investigating
expression of superoxide dismutase-2 (SOD-2), a cellular mitochondrial scavenger.
Immunofluorescence staining of SOD-2 in hCM showed that this protein was expressed
in both normal and high glucose cultures (Figure 4.5). Western blotting protein analysis
of SOD-2, also confirmed this, as there was no difference in expression between groups.
4.3.4 Apoptosis and Autophagy
Programmed cellular apoptotic death and autophagic organelle recycling were
assessed in hCM normal and high glucose cultures to see if high glucose conditions
induced these outcomes, as seen in diabetic conditions. Immunofluorescence staining for
caspase-3, an apoptosis marker, illustrated higher caspase-3 expression in high glucose
hCM when compared to normal glucose hCM (Figure 4.6). Examination of caspase-3 in
protein lysates by an assay revealed an upward trend of apoptosis in hCM in high
glucose, however western blotting of caspase-3 western blotting showed no difference
between the two groups. Visualization of light chain 3B (LC3B), an autophagy marker,
was performed with the LC3B Antibody Kit for Autophagy and showed increased
expression in high glucose hCM (Figure 4.7). Western blotting investigation of LC3B
demonstrated an upward trend with high glucose conditioning of hCM compared to
normal hCM.
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Figure 4.4: Endoplasmic reticulum stress examination in normal and high glucose hCM
culture. Western blotting of protein kinase RNA-like endoplasmic reticulum kinase
(PERK), an ER stress marker. RDU= relative densitometry units.
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Figure 4.5: Analysis of superoxide dismutase-2 (SOD-2) antioxidant defense in high and
normal glucose hCM cultures. (A) Immunofluorescence staining of SOD-2 (green) with
DAPI (blue) nuclei staining of hCM. Negative controls not shown. (B) Western blotting
for SOD-2 expression in hCM culture. RDU=relative densitometry units.
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Figure

4.6:

Apoptosis

in

hCM

normal

and

high

glucose

culture.

(A)

Immunofluorescence for caspase-3 (green), an apoptosis marker, with DAPI (blue) nuclei
staining in hCM culture. Negative controls not shown. (B) Caspase-3 assay and (C)
western blotting was used for caspase-3 for apoptosis detection in normal and high
glucose conditioning of hCM. RDU=relative densitometry units.
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Figure 4.7: Autophagy investigation in high and normal glucose environments for hCM.
(A) Autophagy visualization in hCM employing light chain 3B (LC3B, green) Antibody
Kit for Autophagy staining with nuclei staining via DAPI (blue). Negative controls not
shown. (B) Western blotting of hCM protein lysates for LC3B, an autophagy marker.
RDU=relative densitometry units.
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4.4 Discussion
Cell culture has provided a simple and controllable in vitro model over the years
to study normal cellular function and disease related alterations that occur within specific
cardiac cell types, such as CMs, fibroblasts, endothelial, and smooth muscle cells.17–19
These studies have provided starting points for research into regulatory pathways
important for healthy cell function, as well as underlying mechanisms of pathological
disease progression. Modifications at the micro cellular level ultimately lead to macro
functional problems at the tissue, organ, and system levels. Understanding how
specialized cells within a tissue operate and adapt within a disease are the keys to
diagnosis of the patient and provide targets for treatment.
While cell culture is great for initial studies, its simplistic and static nature does
have some pitfalls. The human body is a highly complicated and dynamic machine with
many mechanisms still to be understood. Cell culture models are reproducible and cell
media is easily tailored with the addition of chemicals, however diseases exist on a
spectrum and across multiple systems in the body.20 Media does not include important
aspects, such as paracrine factors from other cells. Crosstalk via paracrine factors
between cells and cell types within an altered state can influence how they themselves
change in response, such as CM hypertrophy and fibroblast proliferation in cardiac
disease.21 In standard culture, cells are grown on a 2D negatively charged polystyrene
surface. Extracellular matrix components, such as collagen and fibronectin, can be used
as surface coatings to better mimic the physiologic environment, however, this still does
not capture the sophistication of the human body.22
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We sought to investigate and characterize cells in an in vitro 2D DCMP model
before pursuing usage within a more complicated 3D in vitro disease model. Early
alterations of CMs are still not understood within this disease, making it difficult to
determine targeted therapies and diagnostic markers for DCMP.23 Throughout the years,
CMs, such as neonatal rat CMs, iPSCs differentiated into CMs, progenitor CMs,
immortalized CMs, and ESCs, have been utilized by many research groups for
understanding cellular adaptations in myocardial diseases as well as diabetic studies.10,13–
15,24,25

For our study we decided to use human progenitor CMs (hCMs), as they were

commercially available, able to expand in culture, adult human cells, and there were no
ethical concerns attached, like ESCs.16 It is important to note that while these cells are
isolated from adult hearts, they have characteristics unlike adult CMs, such as the ability
to proliferate and potential to differentiate. These specific cells from the manufacturer
have been used for many applications such as inflammatory, hypoxic, metabolic, toxicity,
and pharmacological studies.13,26–31
For this preliminary study of a simple 2D DCMP model, the “diabetic”
environment was produced by the addition of glucose to culture media. After two weeks,
cells were analyzed for alterations known to exist within DCMP, such as lipid
accumulation and peroxidation, ROS formation, increased cell death and autophagy,
accumulation of AGEs with increased expression of their receptor, RAGE, endoplasmic
reticulum (ER) stress, changes in endogenous antioxidant defense mechanisms, and
lessened MMP activity.32,33 This was performed to determine if these cells would be
suitable for future studies.
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Hallmarks of diabetes and DCMP include the accumulation of AGEs and
increased expression of its receptor, RAGE.34,35 The hyperglycemic environment leads to
the buildup of these irreversible crosslinks, which can detrimentally alter the extracellular
matrix.36 As the diabetic state is highly inflammatory, RAGE becomes overexpressed via
a positive feedback cycle.37 This was also shown to be the case within our in vitro model
as CML, an AGE, and RAGE expression were increased when cultured in high glucose.
We also investigated MMP activity, as in DCMP it is inhibited.38 Within our model, there
was a downward trend in the high glucose groups.
Hyperglycemia and dyslipidemia in diabetes cause loss of metabolic plasticity,
leading to a surge in usage of free fatty acids.32 From this imbalance oxidative stress, ER
stress, lipid peroxidation, and lipid aggregation originate.5 There were noted increases of
all these features, except for ER stress, in the high glucose cultures of hCM. Increases in
all of these traits have been previously reported in high glucose studies involving
neonatal and adult rat CMs, hiPSCs, and progenitor hCM sourced from the same
company.10,12,13,39,40 ER stress was not shown to be increased in high glucose cell culture
conditions, however this study was only for two weeks and only a marker for one of three
pathways activated by ER stress was investigated. It may be worthwhile to look at other
pathway markers, as they may activated at earlier timepoints.
These metabolic disturbances and unbalanced state can lead to overwhelmed
antioxidant defense mechanisms followed by enhanced cellular organelle recycling via
autophagy and increased programmed cell death through apoptosis.6,41 There were no
differences seen in the expression of SOD-2, an endogenous mitochondrial defense
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mechanism, between the two groups within two weeks. Autophagy and apoptosis were
increased in high glucose hCM. Escalation of apoptosis in inflated glucose conditions has
been seen in hiPSCs differentiated into CMs and neonatal rat CMs.10,11
4.5 Conclusions
Cell culture is a good stepping stone for initial investigations of homeostatic
cellular functions and pathological alterations of specific cell types, however it is unable
to recapitulate the complexity or diversity of the human body. Progenitor hCM utilized
for this preliminary study responded to the “diabetic” environment induced with the
addition of glucose for two weeks. They will be useful in building a tissue engineered
DCMP model to study early cellular changes in a 3D and dynamic in vitro model.
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CHAPTER 5: ELECTROMECHANICAL BIOREACTOR FOR CARDIAC
TISSUE ENGINEERING
5.1 Introduction
Tissue engineering holds a great promise to regenerate myocardial tissue in order
to replace and restore function to the diseased tissue. To do this a robust system is needed
to condition the construct (i.e. the scaffold and cells) prior to implantation for tissue
maturation. Physiological electromechanical stimuli are crucial in this process as they
improve maturation, structure, and function of cardiomyocytes (CMs) in vitro.1 Electrical
stimulation of CMs has been shown to affect cell alignment, differentiation, metabolic
activity, protein synthesis, connexin 43 expression, conduction velocity, calcium
handling, and force generation.2 These changes have been induced with physiological
electrical properties such as rectangular shape and 2ms duration at 5V/cm and 1Hz.3
Mechanical strain is important for CM alignment and development and expression of ttubules, myofilaments, sarcomeric organization, gap junctions, desmosomes, adherens
junctions.4
As of now, combinational electromechanical bioreactors have only tested animal
cells in gels at low cyclic stretch or decellularized myocardium for a short duration.5,6
However, many discrepancies exist between animal and human CMs, gels may not
withstand the highly dynamic environment seen in vivo, and scaffolds tested would be
too small to be translatable for use in a human patient.7,8 To meet this need, we developed
a physiologically relevant electromechanical bioreactor system. We hypothesized that by
combining this with a methodology for reproducible myocardial-like tissues utilizing
decellularized porcine myocardium, previously developed in our lab, seeded with human
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CMs we would be able to create a robust platform for tissue engineered myocardium
preconditioning.
5.2 Materials and Methods
5.2.1 Materials
Primary human cardiac myocytes (hCM) were from Promocell GmbH
(Heidelberg,

Germany).

Dulbecco’s

Modified

Eagle

Medium

(DMEM)

and

antibiotic/antimycotic were from Corning Incorporated (Oneonta, NY). Fetal Bovine
Serum (FBS) was from Atlanta Biologicals (Atlanta, GA). A FX-5000™ Compression
System and Bioflex® 6-well plates were from Flexcell International Corp. (Burlington,
NC, USA). Bicinchoninic acid protein assay was from Pierce Biotech (Rockford, IL).
Carbon electrodes were from Alfa Aesar (Haverhill, MA). Platinum wire was purchased
from Ladd Research Industries (Williston, VT). The Vectastain Elite kit, ABC
diaminobenzidine tetrahydrochlorine peroxidase substrate kit, and Vectashield mounting
medium were from Vector Laboratories (Burlingame, CA). The following antibodies
were used: rabbit anti-sarcomeric α-actinin (Abcam, ab90776), rabbit anti-connexin-43
(Abcam, ab11370), rabbit anti-GATA-4 (Abcam, ab84593), rabbit anti-desmin (Abcam,
ab15200), rabbit anti-laminin (Abcam, ab11575), and rabbit anti-collagen IV (Abcam,
ab6586). Biotinylated anti-rabbit IgG was purchased from Vector Laboratories
(Burlingame, CA). Movat’s Pentachrome Kit and Masson’s Trichrome Kit were from
Poly Scientific (Bay Shore, NY). All other chemicals were of the highest purity and
purchased from Sigma-Aldrich Corporation (Lakewood, NJ).
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5.2.2 Decellularization of Porcine Myocardium Scaffold
Whole, healthy, porcine hearts were obtained from a local abattoir and
decellularized utilizing a previously published method.9 Briefly, after harvesting whole
hearts were immediately injected with warm 50mM ethylenediamenetetraacetic acid
(EDTA) in phosphate buffered saline (PBS) into the coronary arteries to prevent clotting.
Hearts were transported on ice for processing. Pulmonary veins were cannulated with a
threaded plug and zip-ties, to ensure proper circulation of solution and decellularization
through the left side of the heart. Excess adipose and connective tissue were cleaned from
the aorta, aortic leaflets were removed, and aorta was connected to a perfusion
decellularization system. The hydrostatic driven perfusion decellularization system
contained a multichannel peristaltic pump (Masterflex; Cole-Parmer) and a series of
reservoirs that circulated 3.5L of solution through and around each heart (Figure 5.1).
Decellularization was performed utilizing 1% sodium dodecyl sulfate (SDS) solution
changes and a DNAse/RNase treatment. Distilled deionized water (ddH2O) and PBS were
employed for washes. Scaffolds were stored in PBS with 0.02% sodium azide and
0.001% protease inhibitor cocktail (Sigma) at 4 degrees C until tissue preparation.
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Figure 5.1: Decellularized porcine myocardium scaffold preparation. (A) Whole heart
perfusion decellularization setup utilizing hydrostatic pressure and peristaltic pump. (B)
Container housing one heart. (C) System can decellularize three hearts simultaneously.
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5.2.3 Tissue Preparation and Sterilization
Decellularized porcine myocardium from the left ventricle was sliced to 2mm by
4cm by 2 cm via a specialized tissue slicer. Briefly, the scaffold was cut into 4 cm by 2
cm pieces using a 3D printed template. These constructs were placed flat on aluminum
foil at -20 degrees Celsius until frozen, then cut into 2 mm slices utilizing microtome
blades integrated into a custom tissue slicer designed in SolidWorks and 3D printed in
digital acrylonitrile butadiene styrene (ABS). After sizing, the tissue was washed in three
rinses of PBS (30 min, 2 hr, 30 min) and then sterilized in sterile 0.01% peracetic acid in
PBS for 2 hours. Excess peracetic acid was removed through three washes of sterile PBS
(30 min, 2hr, 30 min). Scaffolds were stored in sterile PBS at 4 degrees Celsius until cell
seeding preparation.
5.2.4 Adaptation of Flexcell Bioflex® 6-Well Plates for Tissue and Electrode Integration
To accommodate cell-seeded scaffolds and an electrical stimulus similar to
physiological conditions, Flexcell Bioflex® 6-well plates were modified. Digital ABS
plastic inserts with lock-in-groove rings were designed using SolidWorks, 3D printed, to
hold constructs in place via a clamping mechanism. The inserts were designed to hold
two cylindrical (cut to 3 mm diameter) carbon electrodes parallel to each other to transfer
an electrical stimulus across the cell-seeded scaffold in each well. Flexcell Bioflex® 6well plates were cut for addition of a positive/negative connector for connection of
external wires for electrical stimuli. Carbon electrodes were internally connected to the
connector by platinum wire secured around the center of the electrode and covered with
shrink tube and tubing with the lead soldered to a positive or negative wire. The positive
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and negative wires from the platinum wires were soldered to the connector. Before
ethylene oxide sterilization of the modified Flexcell Bioflex® 6-well plate, continuity
was tested with a voltmeter.
5.2.5 Flexcell FX-5000™ Compression System Modifications
A FX-5000™ Compression System sold by Flexcell International Corporation
was modified to allow for mechanical and electrical stimulation of the hCM cell seeded
decellularized porcine myocardium scaffolds. The system purchased included a baseplate
allowing for four Flexcell Bioflex® 6-well plates with membranes to be sealed airtight
against it. Compressed air travelling through the baseplate served to mechanically
stimulate cells in the wells by pushing the membrane and integrated tissue upward.
Pressure was regulated by the main controller containing pressure regulators, transducers,
and valves.
To more properly model diastole and systole of the left ventricular wall, the cyclic
pressure waveform was modelled using provided Flexcell software, at 1.17 Hz (~70 beats
per minute) with an amplitude of 0-120-0 mmHg (350 msec duration) with a static at 0
mmHg (450 msec duration). A pressure transducer was added to monitor real-time
pressure applied to the silicone membrane and was acquired by a data acquisition module
in a custom-written LabView program. Another LabView program triggered a squarewave electrical pulse of 5V (2.78V/cm2, 20 msec-width) at the rising edge of every
pressure wave for a coordinated pulse.
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5.2.6 Cell Culture, Seeding and Viability
Progenitor human cardiac myocytes (hCMs) were expanded in Dulbecco’s
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1%
antibiotic/antimycotic (penicillin-streptomycin). Sized, sterile, decellularized porcine
myocardium was incubated overnight at 37 degrees Celsius in cell culture medium
comprised of Dulbecco’s Modified Eagle’s medium (DMEM), 10% fetal bovine serum
(FBS), and 1% antibiotic/antimycotic (penicillin-streptomycin). Before seeding, scaffolds
were incubated 2 hours at 37°C in 6 well plates to allow removal of excess medium.
Scaffolds were secured into two modified Flexcell Bioflex® 6-well plates (Flexcell
International Corp., Burlington, NC, USA) and progenitor human cardiomyocytes (hCM)
at passage 6 were aseptically injected (2 million per scaffold) and dropwise seeded (1
million per scaffold) with a sterile 26 ½ gauge needle. Control scaffolds were not seeded
with hCM. Both plates were placed in an incubator for 1 hour to allow for hCM
attachment and 4 mL of cell culture media (DMEM, 10% FBS, 1% Ab/Am) was placed
in each well. Tissue was statically cultured for 3 days before exposure to dynamic
stimuli. Before subjecting tissue (with cells or without cells) to the electrical stimulus and
physiological cyclic pressures (0-120-0 mmHg), preconditioning was performed at two
days with a cyclic waveform of 0-40-0 mmHg, followed by two days of a cyclic
waveform of 0-80-0 mmHg. Media was changed every day and 7 mL was added to each
well to cover the dynamic tissue and account for evaporation. Static scaffolds were
controls and media was changed every day at 4 mL per well. Cell viability was confirmed
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with a LIVE/DEAD® Viability/Cytotoxicity kit for Mammalian Cells from Molecular
Probes (Eugene, OR).
5.2.7 Histological and Immunohistochemical Analysis
Samples were fixed in 10% formalin for 48 hours, processed, paraffin-embedded,
and sectioned to 5um. Sections were rehydrated and examined via histological staining
with hematoxylin and eosin (H&E), Masson’s trichrome and Movat’s pentachrome.
Manufacturer’s protocol was utilized for each stain.
Immunohistochemistry (IHC) was performed for detection of sarcomeric αactinin, connexin-43, GATA-4, desmin, laminin, and collagen IV. Briefly, antigen
retrieval was performed on rehydrated paraffin sections (5um) with heated (90-100
degrees Celsius, 10 min) 10mM citric acid (pH=7.4). Slides were permeabilized with
0.025% Triton X-100 for 5 minutes and then incubated in normal blocking serum for 45
minutes. Primary antibodies (rabbit anti-sarcomeric α-actinin 2ug/mL dilution, rabbit
anti-connexin-43 2ug/mL dilution, rabbit anti-desmin 2ug/mL dilution, rabbit antiGATA-4 4ug/mL dilution, rabbit anti-collagen IV 2ug/mL dilution, or rabbit anti-laminin
4ug/mL dilution) were incubated overnight at 4 degrees Celsius. Negative controls were
obtained by omitting the primary antibody. Endogenous peroxidases were blocked with
0.3% hydrogen peroxide in 0.3% normal horse serum for 30 minutes. The secondary
biotinylated anti-rabbit or anti-mouse antibody was applied for 30 minutes. Antibody
staining was visualized using the Vector ABC peroxidase substrate kit and then lightly
counterstained with diluted hematoxylin, before mounting. A Zeiss Axiovert 40CFL
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microscope with AxioVision Release 4.6.3 digital imaging software (Carl Zeiss
MicroImaging, Inc. Thornwood, NY) was utilized to obtain images.
5.3 Results
5.3.1 Decellularization of Porcine Myocardium Efficacy
To decellularized whole porcine hearts for scaffolds, a perfusion system
previously developed within our group was employed to use the vasculature of the hearts
to perform cellular removal (Figure 5.1).9 With this technique, three whole porcine
hearts can be decellularized simultaneously. This decellularization platform combined
with solutions specific to our method were seen in appearance and histological analysis
of hematoxylin and eosin (H&E), Masson’s trichrome, and Movat’s pentachrome
staining, to eradicate cells and residual materials (Figure 5.2). Our methods were harsh
enough to eliminate cells, while gentle enough to retain the collagenous extracellular
matrix, as shown in Masson’s trichrome and Movat’s pentachrome staining of fresh and
decellularized hearts.
5.3.2 Efficiency of Scaffold Preparation
By utilizing a custom 3D printed tissue slicer with integrated microtome blades,
we were able to separate reproducible 4cm by 2cm by 2mm pieces of decellularized left
ventricular porcine myocardium from endocardium and epicardium (Figure 5.3).
Through our scaffold methodology of decellularization and preparation, hCM seeded on
these scaffolds were viable at 1 hour and 3 days after seeding (Figure 5.4). Cells cultured
statically for 21 days on these scaffolds were alive (Figure 5.8). hCM cultured for 3 days
static, followed by 4 days dynamic conditioning, and then subjected to physiological
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electrical and mechanical conditions for 14 days were also viable on these scaffolds
(Figure 5.8). Few dead cells were found (images not shown).

Figure 5.2: Comparison of fresh and decellularized porcine hearts. Images of hearts
(top). Histological staining of fresh and decellularized tissue (middle to bottom) via
hematoxylin and eosin (H&E; purple=nuclei, pink=tissue), Masson’s trichrome
(red=muscle

fibers,

blue=collagen,

black=nuclei)

and

Movat’s

pentachrome

(black=nuclei or elastic fibers, yellow=collagen or reticular fibers, blue=ground
substance or mucin, bright red=fibrin, red=muscle).
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Figure 5.3: Custom 3D printed tissue slicer for extraction of left ventricular myocardium
from decellularized porcine heart. Images show isolation of decellularized myocardium
from a piece utilizing a template (A) and tissue slicer (B) after clamping frozen tissue in
the system (C) and cutting via secured microtome blades (D, E). The tissue slicer
separated the heart wall into endocardium (F), myocardium (G), and epicardium (H).
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5.3.3 Investigation of Modified Flexcell FX-5000™ Compression System and Plates
By modifying a Flexcell FX-5000™ compression system and Flexcell Bioflex®
6-well plates with membranes, we were able design a platform for electrical and
mechanical stimulation of tissue seeded with hCM. 3D printed ABS well plate inserts
were sturdy for the experimental duration under dynamic and static conditions. These
inserts were able to securely hold the tissue in place for 18 days, as well as provide
housing for carbon electrodes and wiring after cutting excess plastic from the plates
(Figure 5.5). The baseplate of this system holding the altered well plates was able to be
contained within a standard cell culture incubator with room to spare (Figure 5.6).
Additional programs written in LabVIEW to provide electrical stimulus and examine
pressure exerted on the tissue were able to be run on the computer purchased with the
system. Modelling of the electrical pulse between electrodes in COMSOL confirmed
current handling in this system (Figure 5.6). By utilizing a ramping up regimen for
dynamic tissue before physiological conditions, as illustrated in Figure 5.7, this system
supported hCM for 14 days in this state (Figure 5.8).
5.3.4 Cellular Analysis
There was high cell viability after the duration of the experiment in both the
dynamic and static groups seeded with hCM (Figure 5.8). Cells were aligned and found
throughout the tissue in the dynamic group, while cells in the static group were spherical
and not aligned. Few dead cells were found (images not shown). Hematoxylin and eosin
(H&E) staining of both groups showed hCM on the surface and within the scaffold. As
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seen in Figure 5.9, cells in dynamic and static scaffolds stained positive for
cardiomyocyte markers such as connexin-43, sarcomeric α-actinin, desmin, and GATA-4.
5.3.5 Extracellular Matrix Investigation
When investigating scaffolds that were dynamically and statically conditioned,
with or without cells, it was found that samples from all groups all had collagen IV
present, with muscle fibers and elastin ﬁbers missing (Figure 5.10, Figure 5.11).
Scaffolds seeded with hCM stained for nuclei. As visualized by immunohistochemistry
(IHC) staining in Figure 5.10, laminin presence was more noticeable in scaffolds seeded
with cells, when compared to those without cells.

Figure 5.4: Viability of human cardiomyocytes (hCM) after seeding. Live images show
viable (green) hCM after 1 hour (left) and 3 days (right) of static seeding.
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Figure 5.5: Modifications of Flexcell plates and mounting prepared tissue. Uncoated
Flexcell plates cut for insertion of connector (A) for positive and negative wires (C) to
deliver stimulus to electrodes (D). 3D printed tissue holding inserts (F) hold tissue via a
clamping ring (E). All components (B) assembled with tissue (G) and cells are ready for
the modified Flexcell system.
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Figure 5.6: Flexcell setup and monitor. A diagram illustrating the modified Flexcell
setup (A) shows addition of data acquisition (DAQ) devices for monitoring pressure and
delivering electrical stimulus included with the Flexcell controller, monitor, and baseplate
holding modified well plates. An incubator (B) houses the modified well plates clamped
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to the baseplate (C). The system is controlled via a computer and monitor (D) utilizing
Flexcell software to deliver air to the baseplate and an original LabVIEW program to
deliver an electrical stimulus to the tissue. The baseplate can hold up to four well plates
(E). 5 volts travel between the electrodes as shown by COMSOL modelling (F).

Figure 5.7: Workflow of experimental set-up for dynamic and static tissues. Tissue was
preconditioned in the dynamic system for 4 days before electrical stimulus and exposure
to normal native cyclic pressure of a 120mmHg.
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Figure 5.8: Cellular viability and presence in dynamic and static conditions. Live assay
of decellularized porcine myocardium cultured with hCM after 18 days static culture (A)
and 18 days of dynamic culture on side (B), inside (C), and other side (D) of the tissue.
Green= live cells. Hematoxylin and eosin staining of cells (purple) show presence in
tissue (pink) after 18 days of static (E) or dynamic (F) culture.
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Figure 5.9: Cellular analysis of human cardiomyocytes (hCM) in static and dynamic
conditions. Immunohistochemical (IHC) staining of cardiomyocyte markers after 18 days
of static and dynamic culture highlight connexin-43 (CX-43), sarcomeric alpha-actinin
(Sarc. α-actinin), desmin, and GATA-4. (brown=positive; purple=tissue; inserts=negative
controls)
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Figure 5.10: Collagen IV and laminin extracellular matrix analysis on scaffolds
subjected to static and dynamic conditions with and without human cardiomyocytes
(hCM). Immunohistochemical (IHC) staining of collagen IV and laminin in groups.
(brown=positive; purple=tissue; inserts= negative controls)
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Figure 5.11: Extracellular matrix investigation of static and dynamic scaffolds with and
without human cardiomyocytes (hCM). Masson’s trichrome (red=muscle fibers,
blue=collagen, black=nuclei) and Movat’s pentachrome (black=nuclei or elastic fibers,
yellow=collagen or reticular fibers, blue=ground substance or mucin, bright red=fibrin,
red=muscle) staining.
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5.4 Discussion
Cardiac tissue engineering has emerged as a promising solution for a functional
tissue replacement for patients who have experienced a myocardial infarction, which
causes myocardial ischemia. Preconditioning is important in developing an engineered
tissue that is mature and behaves properly when implanted.10 Electrical and mechanical
stimuli have been proven to be pivotal

in this. Currently,

combinational

electromechanical bioreactors have only tested animal cells encapsulated in gels at low
cyclic stretch or seeded in decellularized tissue for a short amount of time.56 Though,
many discrepancies exist between animal and human CMs, physiological conditions
could destroy weak gels, and these platforms support small tissues, limiting their
translation to human patients.7,8
To fill this disparity, we developed a physiologically relevant bioreactor that was
able to subject larger (4cm by 2cm by 2mm) and mechanically sound scaffolds with
human cells. Within our lab we have produced a complex 3D acellular scaffold from
decellularized porcine myocardium, which has been proven to retain mechanical and
vascular integrity, and important ECM basal lamina components crucial to recapitulating
native myocardium, such as fibronectin, laminin, and collagen IV.9 Myocardial ECM is
very diverse and this specific environment is essential for inherent cellular interactions
and tethering.11,12 By designing a tissue slicer we were able to simply and reproducibly
extract myocardium from our scaffold at around a 2mm thickness.
For our cells we decided to employ primary hCM progenitor cells. They have
recently been used for research in areas such as cardiotoxicity, therapeutic testing,
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scaffold biocompatibility, and the study of pathways involved in oxidative stress.13–16
These cells are more cost effective than induced pluripotent stem cells (iPSCs), can
proliferate, and express cardiac markers, such as sarcomeric α-actin, making them ideal
for our research.17
We were able to create tissue engineered myocardium my combining hCM and
our scaffold. This myocardium was supported in our electromechanical bioreactor for 14
days at physiologically relevant conditions with mechanical and electrical stimuli after an
initial ramping up period in order to acclimate the hCM to this highly dynamic
environment. Not only was this system able to maintain viable cells for 14 days, but
dynamic scaffolds had live hCM throughout the tissue and on both surfaces that were
aligned, while statically cultured tissue engineered myocardium had spherical cells
localized to one surface. Morphologically, our dynamic myocardium is more similar to
cellular alignment of native myocardium and with this system we can support these cells
within our 2mm thick tissues.
CM markers were evaluated as a checkpoint to determine if our electromechanical
bioreactor allowed for the preservation of the CM phenotype in our scaffolds. To do so
we investigated connexin 43, sarcomeric α-actinin, desmin, and GATA-4 in dynamic and
static conditions. Connexin 43 or gap junction protein, plays a key role in synchronous
cellular contraction and the exchange of molecules, such as calcium, between cells.18,19
Sarcomeric α-actinin and desmin are integral parts of the sarcomere in CMs and
contribute to its contraction and overall functionality.19–21 GATA-4 is crucial for CM
development, differentiation, as it is only expressed by CMs and is a transcriptional
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regulator for cardiac genes.16,19 These proteins were all found to be expressed by hCM in
scaffolds cultured in dynamic or static conditions.
Our scaffold was also inspected with and without cells to determine if our
dynamic conditioning would adversely alter the ECM, as it could compromise overall
function of our tissue engineered myocardium. Scaffolds were not adversely altered in
the course of 14 days within the electromechanical bioreactor. All scaffolds dynamically
and statically conditioned, with and without cells, were shown to retain collagen IV and
laminin, important ECM proteins. Collagen IV provides the supportive framework for the
ECM and cells to interact.22 Laminins are glycoproteins located mainly in the basal
lamina and are vital for cell-ECM attachment, cell differentiation, survival, and
migration.23 Dynamic and static scaffolds with cells had increased expression of laminin
compared to scaffolds without cells, which is promising. This shows the hCM are
integrating and interacting with the ECM, by connecting to and secreting their own
matrix proteins.
5.5 Conclusions
Tremendous strides have been made in cardiac tissue engineering, with even more
to come. We are the first to our knowledge to subject acellular porcine scaffolds seeded
with hCM to physiological electromechanical conditions for 14 days. We found that
dynamic tissues had cellular alignment and cells throughout the tissue, while static tissue
did not. This bioreactor system for myocardium was able to support human cells
expressing cardiomyocyte markers for 14 days at physiological conditions, without
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altering the ECM. This platform has great potential for myocardial tissue preconditioning
and could be useful for disease modeling.

5.6 Chapter 5 References
1
2
3
4
5

6

7
8
9

10
11

12

Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering : State of the art.
Circ Res 2014;114:354–67. https://doi.org/10.1161/CIRCRESAHA.114.300522.
Kofron CM, Mende U. In vitro models of the cardiac microenvironment to study
myocyte and non-myocyte crosstalk: bioinspired approaches beyond the
polystyrene dish. J Physiol 2017;595:3891–905. https://doi.org/10.1113/JP273100.
Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B, et al. Biowire: A
platform for maturation of human pluripotent stem cell-derived cardiomyocytes.
Nat Methods 2013;10:781–7. https://doi.org/10.1038/nmeth.2524.
Zimmermann WH, Schneiderbanger K, Schubert P, Didié M, Münzel F, Heubach
JF, et al. Tissue engineering of a differentiated cardiac muscle construct. Circ Res
2002;90:223–30. https://doi.org/10.1161/hh0202.103644.
Morgan KY, Black LD. Mimicking Isovolumic Contraction with Combined
Electromechanical Stimulation Improves the Development of Engineered Cardiac
Constructs. Tissue Eng Part A 2014;20:1654–67.
https://doi.org/10.1089/ten.tea.2013.0355.
Wang B, Wang G, To F, Butler JR, Claude A, McLaughlin RM, et al. Myocardial
scaffold-based cardiac tissue engineering: Application of coordinated mechanical
and electrical stimulations. Langmuir 2013;29:11109–17.
https://doi.org/10.1021/la401702w.
Fuentes-Antras J, Picatoste B, Gomez-Hernandez A, Egido J, Tunon J, Lorenzo O.
Updating experimental models of diabetic cardiomyopathy. J Diabetes Res
2015;2015:. https://doi.org/10.1155/2015/656795.
Chaudhuri R, Ramachandran M, Moharil P, Harumalani M, Jaiswal AK.
Biomaterials and cells for cardiac tissue engineering: Current choices. Mater Sci
Eng C 2017;79:950–7. https://doi.org/10.1016/j.msec.2017.05.121.
Schulte JB, Simionescu A, Simionescu DT. The acellular myocardial flap: a novel
extracellular matrix scaffold enriched with patent microvascular networks and
biocompatible cell niches. Tissue Eng Part C Methods 2013;19:518–30.
https://doi.org/10.1089/ten.TEC.2012.0536.
Gaetani R, Doevendans PAF, Messina E, Sluijter JPG. Tissue Engineering for
Cardiac Regeneration 2011;6:1–27. https://doi.org/10.1007/8415_2011_82.
Kelly DJ, Rosen AB, Schuldt AJT, Kochupura P V, Doronin S V, Potapova I a, et
al. Increased myocyte content and mechanical function within a tissue-engineered
myocardial patch following implantation. Tissue Eng Part A 2009;15:2189–201.
https://doi.org/10.1089/ten.tea.2008.0430.
Badylak SF. The extracellular matrix as a biologic scaffold material. Biomaterials

130

13

14

15

16
17
18

19

20

21
22
23

2007;28:3587–93. https://doi.org/10.1016/j.biomaterials.2007.04.043.
Hernández-Córdova R, Mathew DA, Balint R, Carrillo-Escalante HJ, CervantesUc JM, Hidalgo-Bastida LA, et al. Indirect three-dimensional printing: A method
for fabricating polyurethane-urea based cardiac scaffolds. J Biomed Mater Res
Part A 2016;104:1912–21. https://doi.org/10.1002/jbm.a.35721.
El-battrawy I, Tülümen E, Lang S, Akin I, Behnes M, Zhou X, et al. Expression of
Inflammation-related Intercellular Adhesion Molecules in Cardiomyocytes In
Vitro and Modulation by Pro-inflammatory Agents. In Vivo (Brooklyn)
2016;30:213–8.
Ruiz-esparza GU, Segura-ibarra V, Cordero-reyes AM, Keith A, Serda RE, Cruzsolbes AS, et al. A specifically designed nanoconstruct associates, internalizes,
traffics in cardiovascular cells, and accumulates in failing myocardium: a new
strategy for heart failure diagnostics and therapeutics. Eur J Hear Fail
2017;18:169–78. https://doi.org/10.1002/ejhf.463.A.
Kuo CY, Chiu YC, Lee AYL, Hwang TL. Mitochondrial Lon protease controls
ROS-dependent apoptosis in cardiomyocyte under hypoxia. Mitochondrion
2015;23:7–16. https://doi.org/10.1016/j.mito.2015.04.004.
Kai D, Prabhakaran MP, Jin G, Ramakrishna S. Biocompatibility evaluation of
electrically conductive nanofibrous scaffolds for cardiac tissue engineering. J
Mater Chem B 2013;1:2305–14. https://doi.org/10.1039/c3tb00151b.
Sarig U, Sarig H, de-Berardinis E, Chaw SY, Nguyen EBV, Ramanujam VS, et al.
Natural myocardial ECM patch drives cardiac progenitor based restoration even
after scarring. Acta Biomater 2016;44:209–20.
https://doi.org/10.1016/j.actbio.2016.08.031.
Lux M, Andrée B, Horvath T, Nosko A, Manikowski D, Hilfiker-Kleiner D, et al.
In vitro maturation of large-scale cardiac patches based on a perfusable starter
matrix by cyclic mechanical stimulation. Acta Biomater 2016;30:177–87.
https://doi.org/10.1016/j.actbio.2015.11.006.
Chan Y-C, Ting S, Lee Y-K, Ng K-M, Zhang J, Chen Z, et al. Electrical
Stimulation Promotes Maturation of Cardiomyocytes Derived from Human
Embryonic Stem Cells. J Cardiovasc Transl Res 2013;6:989–99.
https://doi.org/10.1007/s12265-013-9510-z.
Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, et al.
Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell
Cardiol 2005;39:133–47. https://doi.org/10.1016/j.yjmcc.2005.03.003.
Zamilpa R, Lindsey ML. Extracellular matrix turnover and signaling during
cardiac remodeling following MI: Causes and consequences. J Mol Cell Cardiol
2010;48:558–63. https://doi.org/10.1016/j.yjmcc.2009.06.012.
Mouw JK, Ou G, Weaver VM. Extracellular matrix assembly: A multiscale
deconstruction. Nat Rev Mol Cell Biol 2014;15:771–85.
https://doi.org/10.1038/nrm3902.

131

CHAPTER 6: TISSUE ENGINEERING MODELS OF DIABETIC CARDIAC
PATHOLOGY
6.1 Introduction
There is no cure for DCMP, except for heart transplantation which has a very long wait
list.1 Treatment for this disease is lumped in with other cardiomyopathies and heart
failure, however these therapies only treat the symptoms and downstream complications
that accompany heart failure without addressing origins of the problem.2 As DCMP
progresses, significant changes are seen in heart mass, size and wall thickness, in
conjunction with abnormal diastolic and/or systolic function.3 Patients at the end stage of
DCMP experience symptoms associated with heart failure, such as shortness of breath,
fluid retention, dizziness, and coughing.4 Patients with heart failure have a 5-year
mortality of approximately 50%.1
Understanding the underlying mechanisms in the early stages of DCMP are crucial for
diagnosis and targeted therapies early on. As of now, knowledge of this disease has relied
on rodent models, cell culture models, and cadaveric human patient hearts.5,6 Human
cadaveric hearts with DCMP have been excellent for elucidating end stage cellular and
extracellular changes and rodent and cell culture models have been utilized to fill in the
gaps. Problems arise within rodent models as they have varying progressions of diabetes,
circulating lipid concentrations, cardiomyocyte electrophysiological properties, higher
beats per minute, and inflammatory responses when compared to human diabetic
patients.7–9 Human cells have been studied to investigate specific cell type alterations
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associated with the diabetic environment, however this is an oversimplified 2D static
environment, lacking an extracellular matrix (ECM).10
Tissue engineering holds much promise in bridging this gap. 3D organotypic tissue
engineered models allow for studies of individual cell types in a dynamic, controllable
and repetitive environment.11 Other research groups have tried to fill this need but have
failed to either produce a complex and dynamic 3D ECM environment or have examined
animal cells, instead of human cells.12,13 We hypothesized that if we combined human
cardiomyocytes (hCMs) and an acellular porcine myocardium scaffold within (1) a
perfusion 3D Kube minibioreactor or (2) an electromechanical bioreactor supplemented
with high glucose, that we would be able to detect early alterations associated with
DCMP. These platforms could be useful for determining and testing targeted
therapeutics, as well as markers for prompt diagnosis of DCMP in diabetic patients.
6.2 Materials and Methods
6.2.1 Materials
Primary human cardiac myocytes (hCM) were from Promocell GmbH (Heidelberg,
Germany). Dulbecco’s Modified Eagle Medium (DMEM) and antibiotic/antimycotic
were from Corning Incorporated (Oneonta, NY). Fetal Bovine Serum (FBS) was from
Atlanta Biologicals (Atlanta, GA). 3D Kubes were purchased from Kiyatec (Greenville,
SC). A multichannel peristaltic pump was from Cole-Parmer (Vernon Hills, IL). A FX5000™ Compression System and Bioflex® 6-well plates were from Flexcell
International Corp. (Burlington, NC, USA). Carbon electrodes were from Alfa Aesar
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(Haverhill, MA). Platinum wire was purchased from Ladd Research Industries (Williston,
VT). Bicinchoninic acid protein assay was from Pierce Biotech (Rockford, IL).
Electrophoresis apparatus, gel imager and imaging software, chemicals, and molecular
weight standards were from Bio-rad (Hercules, CA). Clean-BlotTM IP Western Blot
Detection kit was obtained from Thermo Fisher Scientific Inc. (Waltham, MA). The
Vectastain Elite kit, ABC diaminobenzidine tetrahydrochlorine peroxidase substrate kit,
and Vectashield mounting medium were from Vector Laboratories (Burlingame, CA).
The following antibodies were used: rabbit anti-superoxide dismutase-2 (Abcam,
ab13534), rabbit anti-advanced glycation endproducts (Abcam, ab23722), rabbit antilight chain 3B (Abcam, ab48394), rabbit anti-caspase-3 (Millipore, 06-735 and Thermo
Fisher, MA1-16843), mouse anti-N-epsilon-(carboxylmethyl)lysine (R&D Systems,
MAB3247), rabbit anti-inositol-requiring enzyme 1 (Abcam, ab48187), and rabbit antiprotein kinase RNA-like endoplasmic reticulum kinase (Abcam, ab192591). Biotinylated
anti-rabbit IgG and anti-mouse IgG were purchased from Vector Laboratories
(Burlingame, CA). Movat’s Pentachrome Kit and Masson’s Trichrome Kit were from
Poly Scientific (Bay Shore, NY). All other chemicals were of the highest purity and
purchased from Sigma-Aldrich Corporation (Lakewood, NJ).
6.2.2 Decellularization of Porcine Myocardium Scaffold
Whole, healthy, porcine hearts were obtained from a local slaughterhouse and
decellularized utilizing a previously published method (see Chapter 5).14 Briefly,
pulmonary veins were cannulated, excess adipose and connective tissue were cleaned
from the aorta, aortic leaflets were removed, and aorta was connected to a perfusion
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decellularization system. Decellularization was performed with 1% sodium dodecyl
sulfate (SDS) solution changes and a DNAse/RNase treatment. Washes of distilled
deionized water (ddH2O) and PBS were used for cleaning. Scaffolds were stored in PBS
with 0.02% sodium azide and 0.001% protease inhibitor cocktail (Sigma) at 4 degrees
Celsius until tissue bioreactor use in either the 3D Kube minibioreactor or modified
electromechanical Flexcell bioreactor.
6.2.3 Tissue Preparation and Sterilization
For the 3D Kube minibioreactor, decellularized porcine myocardium scaffolds were
removed using a 5mm round biopsy punch. For the electromechanical bioreactor,
decellularized porcine myocardium was extracted from the left ventricle was sliced to
2mm by 4cm by 2 cm via a specialized tissue slicer (see Chapter 5). Briefly, the scaffold
was cut into 4 cm by 2 cm pieces using a 3D printed template, frozen at 20 degrees
Celsius, then cut into 2 mm slices with a custom designed 3D printed tissue slicer.
After isolation, the scaffolds were washed in three rinses of PBS (30 min, 2 hr, 30 min)
and then sterilized in sterile 0.01% peracetic acid in PBS for 2 hours. Excess peracetic
acid was removed through three washes of sterile PBS (30 min, 2hr, 30 min). Scaffolds
were stored in sterile PBS at 4 degrees Celsius until cell seeding preparation.
6.2.4 Adaptation of Well Plates and FX-5000™ Compression System Modifications
To accommodate cell-seeded scaffolds and an electrical stimulus like physiological
conditions, Flexcell Bioflex® 6-well plates were modified as previously described (see
Chapter 5). Briefly, inserts were designed to hold constructs in place and to hold two
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wired carbon electrodes parallel to each other to transfer an electrical stimulus across the
cell-seeded scaffold in each well. Flexcell Bioflex® 6-well plates were cut for addition of
a positive/negative connector for connection of external wires and electrodes were
bridged with platinum wires for electrical stimuli. Continuity was tested with a voltmeter
and plates were sterilized with ethylene oxide.
A FX-5000™ Compression System sold by Flexcell International Corporation was
modified to allow for mechanical and electrical stimulation of the hCM cell seeded
decellularized porcine myocardium scaffolds (see Chapter 5). The cyclic pressure
waveform to mimic diastole and systole of the left ventricular wall was modelled using
provided Flexcell software, at 1.17 Hz (~70 beats per minute) with an amplitude of 0120-0 mmHg (350 msec duration) with a static at 0 mmHg (450 msec duration). This was
confirmed with the addition of a pressure transducer and a data acquisition module in a
custom-written LabView program. Another LabView program triggered a square-wave
electrical pulse of 5V (2.78V/cm2, 20 msec-width) at the rising edge of every pressure
wave for a coordinated pulse.
6.2.5 Cell Culture and Expansion
Progenitor human cardiac myocytes (hCMs) were expanded in normal glucose. They
were then cultured for 14 days in normal glucose or high glucose media before seeding
on prepared and sterilized decellularized porcine myocardial scaffolds. Normal and high
glucose media constituted of Dulbecco’s Modified Eagle Medium (DMEM), 10% Fetal
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Bovine Serum (FBS), and 1% antibiotic/antimycotic (penicillin-streptomycin), with 5mM
(1g/L) and 25mM (4.5g/L) glucose, respectively.
6.2.6 3D Kube Minibioreactor Setup
For the 3D Kube minibioreactor systems, sterile scaffolds were then placed in normal
glucose media constituted of DMEM, 10% FBS, and 1% antibiotic/antimycotic
(penicillin-streptomycin) overnight at 37 degrees Celsius. The next day, these scaffolds
were injected with a 26½ gauge needle aseptically with hCM with 200,000 cells per
scaffold. After 48 hours of static resting in either normal (n=11) or high (n=10) glucose
media, two bioreactors (one normal and one with high glucose media) were aseptically
assembled utilizing 3D Kubes to house the respective reseeded scaffolds. The bioreactors
were housed in an incubator (37°C, 5% CO2). A multi-channel peristaltic pump provided
a flow rate of 1mL/min from a fluid reservoir. 1% antibiotic/antimycotic was injected
every 3.5 days into the closed system to replenish degraded antibiotics and media was
changed every week for each bioreactor. The scaffolds were subjected to these conditions
for 14 days then analyzed (Table 6.1). Cell viability was confirmed with a
LIVE/DEAD® Viability/Cytotoxicity kit for Mammalian Cells from Molecular Probes
(Eugene, OR).
3D Kube Minibioreactor
Conditions
# Samples: Protein # Samples: Histology # Samples: Live/Dead # Samples: Cryosections
Normal Glucose
6
2
1
1
High Glucose
6
2
1
1

Table 6.1: Sample size and analysis for 3D Kube minibioreactor.
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6.2.7 Electromechanical Bioreactor Setup
Sized, sterile, decellularized porcine myocardium was incubated overnight at 37 degrees
Celsius in cell culture medium comprised of Dulbecco’s Modified Eagle’s medium
(DMEM), 10% fetal bovine serum (FBS), and 1% antibiotic/antimycotic (penicillinstreptomycin). Before seeding, scaffolds were incubated 2 hours at 37°C in 6 well plates
to allow removal of excess medium. Scaffolds were secured into two modified Flexcell
Bioflex® 6-well plates (Flexcell International Corp., Burlington, NC, USA) and
progenitor human cardiomyocytes (hCM) at passage 6 were aseptically injected and
dropwise seeded (2 million per scaffold) with a sterile 26 ½ gauge needle. Plates were
placed in an incubator for 1 hour to allow for hCM attachment and then 4 mL of cell
culture media (normal or high glucose, depending on expansion conditions) was added to
each well. Tissue was statically cultured for 3 days before subjecting tissue cultured in
either normal or high glucose to preconditioning in the bioreactor. Preconditioning was
performed with a cyclic waveform of 0-40-0 mmHg for two days, followed by two days
with a cyclic waveform of 0-80-0 mmHg, and then tissue engineered myocardium was
subjected to 0-120-0 mmHg cyclic waveform with electrical stimuli for 14 days. Normal
and high glucose media was changed every day and 7 mL was added to each well to
cover the dynamic tissue and account for evaporation. Cell viability was confirmed with a
LIVE/DEAD® Viability/Cytotoxicity kit for Mammalian Cells from Molecular Probes
(Eugene, OR). Samples were divided and processed for analysis (Table 6.2, Figure 6.1).
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Electromechanical Bioreactor
Conditions
# Samples: Protein, RNA, and Histology # Samples: Live/Dead, Cryosections
Normal Glucose
11
1
High Glucose
11
1

Table 6.2: Sample size and analysis for electromechanical bioreactor.

Figure 6.1: Division of electromechanical scaffolds for analysis.

6.2.8 Histological Analysis
After 14 days in either the 3D Kube minibioreactor or electromechanical bioreactor,
normal and high glucose samples were fixed in 10% formalin for 48 hours and
histologically processed, paraffin embedded, and sectioned on slides. Rehydrated paraffin
sections (5um) were stained with hematoxylin and eosin (H&E), Movat’s pentachrome,
and Masson’s trichrome kits for normal and high glucose samples. Manufacturer’s
guidelines were followed for these.
Immunohistochemistry (IHC) was performed for detection of superoxide
dismutase-2 (SOD-2), light chain 3B (LC3B), carboxymethyl lysine (CML), inositol-
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requiring enzyme 1 (IRE-1) and caspase-3 to compare high and normal glucose samples.
Briefly, antigen retrieval was performed on rehydrated paraffin sections (5um) with
heated (90-100 degrees C, 10 min) 10mM citric acid (pH=7.4). Slides were
permeabilized with 0.025% Triton X-100 for 5 minutes and then incubated in normal
blocking serum for 45 minutes. Primary antibodies (rabbit anti-SOD-2 1ug/mL dilution,
rabbit anti-LC3B 5ug/mL dilution, rabbit anti-IRE-1 4ug/mL, mouse anti-CML 2ug/mL,
or rabbit anti-caspase-3 4ug/mL dilution) were incubated overnight at 4 degrees Celsius.
Negative controls were obtained by omitting the primary antibody. Endogenous
peroxidases were blocked with 0.3% hydrogen peroxide in 0.3% normal horse serum for
30 minutes. The secondary biotinylated anti-rabbit antibody was applied for 30 minutes.
Antibody staining was visualized using the Vector ABC peroxidase substrate kit and then
lightly counterstained with diluted hematoxylin, before mounting. A Zeiss Axiovert
40CFL microscope with AxioVision Release 4.6.3 digital imaging software (Carl Zeiss
MicroImaging, Inc. Thornwood, NY) was utilized to obtain images.
6.2.9 Lipid Staining
Lipid accumulation was visualized in both bioreactor system samples via oil red O on
cryosectioned normal and high glucose samples. Slides were fixed in 4%
paraformaldehyde, rinsed in distilled, deionized water (ddH2O), rinsed in 60%
isopropanol, and stained in 0.3% Oil Red O in isopropanol solution. Slides were then
rinsed twice in 60% isopropanol, stained in a 1 to 1 hematoxylin in ddH2O solution,
rinsed in ddH2O, and mounted with aqueous Vectashield mounting medium. Light
images were taken on a Zeiss Axiovert 40CFL microscope, as described before.
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6.2.10 Detection of Caspase-3, SOD-2, CML, AGE, LC3B, and PERK
Western blotting was employed to compare amounts of caspase-3, SOD-2, CML,
advanced glycation endproducts (AGEs), LC3B, and protein kinase RNA-like
endoplasmic reticulum kinase (PERK) between normal glucose and high glucose
conditioned samples run in the electromechanical bioreactor for 14 days. Proteins were
extracted by radioimmunoprecipitation assay (RIPA) extraction buffer (50mM Tris-HCl
pH 7.4, 150mM sodium chloride (NaCl), 1mM ethylenediaminetetraacetic acid (EDTA),
1% Triton X-100, 1% Sodium Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), with
protease inhibitor cocktail). Protein concentrations in the samples were found using a
bicinchoninic acid protein (BCA) assay. For each sample, 20ug of protein per lane was
loaded and a pre-stained molecular weight standard was loaded in one of the lanes.
Protein from the gels were transferred to polyvinylidine fluoride membranes. Primary
antibodies (mouse anti-caspase-3 1ug/mL, rabbit anti-SOD-2 1ug/mL, mouse anti-CML
1ug/mL, rabbit anti-AGE 1ug/mL, rabbit anti-LC3B 1ug/mL, or rabbit anti-PERK
1ug/mL) were applied overnight at 4°C. The secondary antibody from the antimouse/rabbit kit was then applied for 45 minutes at room temperature. The
polyvinylidine fluoride membranes were fluorescently tagged with detection solution
from the anti-mouse/rabbit kit (1 minute) and then imaged using the Chemi-Doc™ XRS+
system from Bio-rad (Hercules, CA). Relative band intensities were determined using
Bio-rad Image Lab Software Version 5.1, beta build 1 and values were analyzed.
Relative amounts of caspase-3 between groups in the electromechanical
bioreactor were examined with the ApoTarget Caspase-3 / CPP32 Colorimetric Protease
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Assay from Invitrogen (Carlsbad, CA). Manufacturer’s protocol was followed. Total
protein was measured via a BCA assay and 100ug was used per sample (n=5 per group).
Intensities were measured using the Synergy H1 Hybrid Reader System from BioTek
(Winooski, VT).
6.2.11 Matrix Metalloproteinase Activity Analysis
Matrix Metalloproteinase (MMP) activity in high and normal glucose media and tissue
protein lysates were analyzed by gelatin zymography. For media analysis, 10uL of
normal or high glucose media per sample was loaded into a gelatin zymography gel with
1x sample buffer. For protein lysate analysis, 20ug of protein was loaded. A pre-stained
molecular weight standard was loaded into a separate lane for each gel. After
electrophoresis separation, the zymography gel was washed in a triton-X solution and
MMPs were activated with a brij-35 development buffer for 24 hours at 37 degrees
Celsius. After staining with Coomassie and destaining, MMP clear bands were imaged
using the Chemi-Doc™ XRS+ system and evaluated by densitometry using the using
Bio-rad Image Lab Software.
6.2.12 Statistical Analysis
Results are expressed at mean ± standard deviation (SD). Statistical analysis was
performed between groups utilizing Welch’s two-tailed t-test in excel. Significance was
determined with an alpha (α) value of 0.05.
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6.3 Results
6.3.1 3D Kube Minibioreactor Results
6.3.1.1 Analysis of Cell Seeding and Viability in 3D Kube Minibioreactor
Constructs were placed in either a high or normal glucose 3D Kube
minibioreactor under perfusion conditions in an incubator (Figure 6.2). Before placing
hCM seeded scaffolds into the 3D Kube minibioreactor, analysis of cell viability was
performed after sitting statically for 48 hours to allow for hCM attachment. As seen in
Figure 6.3, hCMs seeded in the scaffold were viable at 48 hours after injection. Scaffolds
from both high and normal glucose dynamically conditioned in the 3D Kube
minibioreactor for 14 days had live cells (Figure 6.3). As revealed in Figure 6.4,
hematoxylin and eosin (H&E) staining of these samples after conditioning showed hCM
within the decellularized porcine myocardium scaffolds.
6.3.1.2 Investigation of Matrix Metalloproteinase Activity and AGEs
Matrix metalloproteinase (MMP) activity and advanced glycation endproduct
(AGE) formation within high and normal glucose 3D Kube minibioreactor samples were
determined with a gelatin zymography and protein western blotting analysis, respectively.
As shown in Figure 6.5, there were no significant differences between groups in overall
MMP, MMP9, and MMP2 activity. Protein analysis of AGEs revealed no significant
differences between the two groups (Figure 6.6).
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Figure 6.2: Set-Up of 3D Kube minibioreactor. (A) Minibioreactor was housed in incubator. (B)
Diagram illustrating media flow in the system. (C) 3D Kube minibioreactor platform fully
assembled with tubing, manifolds, reservoir, and 3D Kubes housing seeded constructs.
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Figure 6.3: Viability analysis of hCM seeded on decellularized porcine myocardium scaffolds.
Static seeding after 48 hours (top), and dynamic minibioreactor conditioned normal (middle) and
high (bottom) glucose after 14 days. (green=live cells, red=dead cells).
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Figure 6.4: Hematoxylin and eosin (H&E) staining of samples after 14 days in 3D Kube
minibioreactor. Normal (left) and high (right) glucose showed cells (purple) and tissue (pink).

6.3.1.3 Antioxidant Defenses and Lipid Accumulation
Antioxidant defense mechanisms were investigated with immunohistochemical
(IHC) staining and western blotting for protein analysis. Superoxide dismutase 2 (SOD2), an endogenous antioxidant defense mechanism, was shown to be present in both high
and normal glucose samples stained via IHC (Figure 6.7). SOD-2 had an upward trend in
the high glucose group as seen in western blotting. Lipid accumulation was visualized
with staining and was only found in high glucose samples (Figure 6.8).
6.3.1.4 Examination of Apoptosis and Autophagy
Caspase-3 was employed to determine programed death or apoptosis within samples.
This protein was present in both normal and high glucose conditioned groups, as seen
with IHC staining (Figure 6.9). IHC staining of samples for light chain 3B (LC3B), an
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autophagic marker, revealed its presence in both groups (Figure 6.10). Western blotting
analysis showed significantly higher expression of LC3B in the high glucose group.

Figure 6.5: Overall matrix metalloproteinase (MMP), MMP9, and MMP2 activity in 3D Kube
normal and high glucose media via gelatin zymography. RDU= relative densitometry units.
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Figure 6.6: Detection of advanced glycation endproducts (AGEs) in 3D Kube minibioreactor
samples by employing western blotting. RDU= relative densitometry units.
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Figure 6.7: Investigation of antioxidant superoxide dismutase 2 (SOD-2) in 3D Kube normal and
high glucose groups. (A) Immunohistochemical (IHC) staining of samples for SOD-2
visualization. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) SOD-2 protein
western blotting analysis of the two groups. RDU= relative densitometry units.
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Figure 6.8: Staining for lipid accumulation in normal and high glucose samples. Red= lipids.

Figure 6.9: Visualization of apoptosis marker caspase-3 in normal and high glucose 3D Kube
minibioreactor samples via immunohistochemistry (IHC). (brown=positive, dark purple=nuclei;
inserts=negative controls).
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Figure 6.10: Inquiry of light chain 3B (LC3B), a marker of autophagy, between 3D Kube groups.
(A) Immunohistochemical (IHC) staining of samples for LC3B. (brown=positive, dark
purple=nuclei; inserts=negative controls) (B) Western blotting analysis of LC3B in groups.
RDU= relative densitometry units. * indicates statistical difference.
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6.3.2 Electromechanical Bioreactor Results
6.3.2.1 Analysis of Cell Seeding and Viability in Electromechanical Bioreactor
Before mounting into the electromechanical bioreactor, we determined that hCM
seeded on decellularized porcine myocardium were viable after one hour and three days
after static seeding (Figure 6.11). After 14 days under dynamic conditions, engineered
tissues contained live cells in both normal and high glucose conditions (Figure 6.12).
Trichrome and pentachrome staining both showed hCM integrated within the collagen
ECM scaffold (Figure 6.13).
6.3.1.2 Investigation of Matrix Metalloproteinase Activity and AGEs
MMP activity and accumulation of AGEs were examined in electromechanically
stimulated normal and high glucose conditioned engineered tissues and media. When
investigating MMP activity in media samples, there were no differences found between
the two groups for overall MMP, MMP9 and MMP2 activity (Figure 6.14). MMP
activity in tissue lysates showed no significant difference in overall MMP, MMP9, and
active MMP2, with significantly higher pro MMP2 and overall MMP2 in high glucose
conditions, as seen in Figure 6.15. Carboxymethyl lysine (CML), an AGE, was shown to
be present in both groups with IHC staining and slightly greater in the high glucose group
with western blot analysis (Figure 6.16). Western blotting for AGE detection indicated
comparable amounts in both groups.
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Figure 6.11: Viability of human cardiomyocytes (hCM) after seeding. Live images show viable
(green) hCM after 1 hour (left) and 3 days (right) of static seeding.

Figure 6.12: Cellular viability after 14 days of electromechanical stimuli in normal and high
glucose conditions. Green= live cells.

6.3.1.3 Examination of Cellular Antioxidant Defenses, Autophagy, and Apoptosis
Cellular changes known as DCMP hallmarks were studied such as antioxidant
defense mechanisms, autophagy, and apoptosis. Superoxide dismutase 2 (SOD-2), an
endogenous antioxidant, was visible in both normal and high glucose bioreactor samples
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with IHC staining (Figure 6.17). SOD-2 protein detection with western blotting revealed
a greater inclination in high glucose samples. IHC staining and western blotting of light
chain 3B (LC3B), an autophagy protein, indicated similar amounts in each group (Figure
6.18). Caspase-3, an apoptosis marker, stained in both groups (Figure 6.19). Protein
analysis of caspase-3 revealed an upward trend in high glucose samples with western
blotting and similar expression in both with a caspase-3 assay.

Figure 6.13: Cell and ECM visualization in electromechanical normal and high glucose samples.
Masson’s trichrome (red=muscle fibers, blue=collagen, black=nuclei) and Movat’s pentachrome
(black=nuclei or elastic fibers, yellow=collagen or reticular fibers, blue=ground substance or
mucin, bright red=fibrin, red=muscle) staining of groups from normal and high glucose
conditions.
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Figure 6.14: Matrix metalloproteinase (MMP) activity in media from electromechanically
conditioned normal and high glucose samples via gelatin zymography. MMP activity results for
all MMPs, MMP9, and MMP2 in media. RDU= relative densitometry units.
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Figure 6.15: Matrix metalloproteinase (MMP) activity in tissue lysates from electromechanically
conditioned normal and high glucose samples via gelatin zymography. MMP activity results for
all MMPs, MMP9, MMP2, proMMP2, and activeMMP2 in tissue. RDU= relative densitometry
units. * indicates statistically significant difference.
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Figure 6.16: Investigation of advanced glycation endproducts (AGEs) in normal and high
glucose groups electromechanically stimulated. (A) Immunohistochemical (IHC) staining of
samples for carboxymethyl lysine (CML), an AGE. (brown=positive, dark purple=nuclei;
inserts=negative controls) (B) Western blotting analysis of CML in groups. (C) Western blotting
analysis for AGE in samples. RDU= relative densitometry units.
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Figure 6.17: Examination of antioxidant superoxide dismutase 2 (SOD-2) in electromechanical
bioreactor normal and high glucose groups. (A) Immunohistochemical (IHC) staining of samples
for SOD-2 visualization. (brown=positive, dark purple=nuclei; inserts=negative controls) (B)
SOD-2 protein western blotting analysis of the two groups. RDU= relative densitometry units.

158

Figure 6.18: Inquiry of light chain 3B (LC3B), a marker of autophagy, between
electromechanical bioreactor groups. (A) Immunohistochemical (IHC) staining of samples for
LC3B. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) Western blotting
analysis of LC3B in groups. RDU= relative densitometry units.
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Figure 6.19: Analysis of apoptosis marker, caspase-3, in electromechanically conditioned normal
and high glucose groups. (A) Immunohistochemical (IHC) staining of samples for caspase-3
visualization. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) Caspase-3
protein western blotting analysis of the two groups. RDU= relative densitometry units. (C)
Results from ApoTarget caspase-3 assay.
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Figure 6.20: Endoplasmic reticulum (ER) stress inspection in normal and high glucose
electromechanical samples. (A) Immunohistochemical (IHC) staining of inositol requiring
enzyme-1 (IRE-1) in samples. (brown=positive, dark purple=nuclei; inserts=negative controls)
(B) Western blotting of protein kinase RNA-like ER kinase (PERK) in the two groups. RDU=
relative densitometry units.
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Figure 6.21: Staining for lipid accumulation in electromechanical bioreactor normal and high
glucose samples. Red= lipids.

6.3.2.4 Endoplasmic Reticulum Stress and Lipid Accumulation
Evaluation of endoplasmic reticulum (ER) stress and lipid accumulation was
performed, as they are traits of DCMP. IHC staining of inositol requiring enzyme-1
(IRE-1), an ER stress marker, showed existence in both normal and high glucose
conditions (Figure 6.20). Western blotting of another ER stress protein, protein kinase
RNA-like ER kinase (PERK) showed no difference between groups. Oil red O staining
revealed lipids within normal and high glucose samples, with more accrual in high
glucose conditions (Figure 6.21).
6.4 Discussion
DCMP is diagnosed once symptoms, including but not limited to, shortness of
breath, angina, and fluid retention, are present in the patient.15 Currently, no cure exists
for DCMP and its treatment is grouped with other heart failures.16 To diagnose and treat
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or even reverse early stages of this disease, understanding the underlying mechanisms of
its progression is key. As of now, animal models and cell cultures have been utilized to
elucidate these initial changes.5 However, there are discrepancies that exist between
rodent models and human patients, such as differing heart beats per minute, circulating
lipid concentrations, CM electrophysiological properties, diabetes disease progression,
and inflammatory response.7 Within rodent models, it is also difficult to study how
individual cell types respond in a diseased state. In cell culture, specific cell types can be
investigated, but it lacks a dynamic 3D ECM environment.
Recently, the field of tissue engineering has moved towards mimicking diseases by
employing organotypic models that are physiologically relevant and reproducible, with
the intent to study specific cell changes within a disease and determine definitive
interactions to halt and reverse disease progression.17–19 Tissue engineering holds
substantial promise for addressing these needs, as it encompasses a wide variety of
disciplines and organotypic 3D models are attractive as they are controllable, repetitive,
and more cost efficient than animal testing.11
Other groups have attempted to bridge this gap for the study of DCMP but have failed to
either produce a complex and dynamic 3D ECM environment or have utilized animal
cells, instead of human cells.10,12,13 Within our lab we have produced a complex 3D
acellular scaffold from decellularized porcine myocardium, which has been proven to
retain mechanical and vascular integrity, and important ECM basal lamina components
crucial to recapitulating native myocardium, such as fibronectin, laminin, and collagen
IV.14 Myocardial ECM is very diverse and this specific environment is essential for
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inherent cellular interactions and tethering.20,21 Cell – ECM interactions in DCMP are
especially pivotal in this disease, as myocardial fibrosis causes CMs to overcompensate
to contract the left ventricle, leading to CM death and hypertrophy.22
Primary hCM progenitor cells have recently been used for research in areas such as
cardiotoxicity, therapeutic testing, scaffold biocompatibility, and the study of pathways
involved in oxidative stress.23–26 They are more cost effective than induced pluripotent
stem cells (iPSCs), can proliferate, and express cardiac markers, such as sarcomeric αactin, making them ideal for CM investigation.27 We have shown these cells respond to
biochemical cues, such as normal (1 g/L) and high (4.5 g/L) glucose, in their milieu (see
Chapter 4).
We examined two DCMP tissue engineering platforms generated within our lab. We
chose to combine hCM and decellularized acellular porcine myocardium in either (1) a
3D Kube perfusion minibioreactor or (2) an electromechanical bioreactor we developed.
3D Kubes have been employed by researchers for disease modelling, tissue angiogenesis
investigations, and cell differentiation and seeding studies.28–31 Our electromechanical
bioreactor has been shown to not alter the CM phenotype or ECM in normal conditions
(see Chapter 5). Each were able to be housed within separate incubators and supported
viable hCM in these scaffolds for 14 days in either normal or high glucose conditions.
To investigate these models, we explored some known hallmarks of DCMP. Within the
hyperglycemic and dyslipidemic diabetic environment there is a loss of metabolic
plasticity and cells rely mainly in free fatty acids for energy.32 This leads to lipid
peroxidation and accumulation, as well as prolonged accrual of reactive oxygen species
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with oxidative stress as antioxidant defense mechanisms are overwhelmed.33 In this
prolonged state, there is an increase in, endoplasmic reticulum (ER) stress, autophagy,
and apoptosis.34,35 Hyperglycemia also increases accumulation of irreversible crosslinks
formed by AGEs and hindered MMP activity, leading to fibrosis.36
In examining early MMP activity and AGE buildup, we saw no differences in overall
MMP activity in media and AGE expression between the normal and high glucose groups
in either bioreactor system. This could be due to the experimental duration of 14 days
being too short to see noticeable changes in AGE accumulation from protein lysates and
overall MMP activity in media. Media analysis could be useful for determining specific
diagnostic markers for patient blood testing. There were no differences in overall MMP,
MMP9, and active MMP2 activity in tissue lysates. We did however, see a significant
increase in overall MMP2 and pro MMP2 activity in high glucose electromechanical
tissue lysates. At this early point we may be seeing initial stages of unbalanced MMP
activity, as MMP2 is heightened in inflammation, and we know later on, in established
diabetic patients’ serum, MMPs are significantly lowered.37,38 We were able to see higher
lipid accumulation within the high glucose tissue in both platforms. This is promising as
this is a trait of diabetes.39
Cellular alterations in hCM such as endogenous antioxidant defense mechanisms,
autophagy, apoptosis, and ER stress were inspected. SOD-2, an endogenous antioxidant
defense mechanism, was slightly elevated in high glucose samples in both systems.
Autophagy was significantly increased within the 3D Kube minibioreactor high glucose
group and no difference was seen between groups in the electromechanical bioreactor.

165

Apoptosis was seen in both states in the minibioreactor system and there was a slight
increase in apoptosis in the high glucose electromechanically conditioned samples. ER
stress was only examined in the electromechanical platform and no differences were
found between groups. In examining early changes, it is important to note that there are
some alterations that may occur before others and some that may not occur until later
stages DCMP. These changes occur over the course of years. Currently, our
understanding of initial stages of this disease is limited and these results are promising as
we know that within the cell, autophagy has been shown to be increased in
hyperglycemia and after a prolonged state, it can lead to apoptosis.40 In evaluating longer
timepoints with these models, we could determine specifically when these modifications
in hCM are occurring in the progression of DCMP.
While this 3D Kube minibioreactor is a promising model for DCMP, there are some
drawbacks with this platform. Due to the small size of the 3D Kube chambers, protein
extraction and analysis is limited, as is sample throughput. Even though this perfusion
system is dynamic in nature, it lacks physiological myocardial conditions such as,
electrical and mechanical stimuli. The electromechanical bioreactor provides these
conditions; however, it is not a perfusion system and media must be changed every day to
support cell viability. Because of this, changes in DCMP and diabetes may not have
shown, as they are caused by accrual of proteins and toxic intermediates within the body.
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6.5 Conclusions
Currently, limitations in animal and cell culture models of DCMP constrain our
understanding of early alterations of specific cell types in this disease. Elucidating initial
modifications are important for targeted therapies and patient diagnosis. Tissue
engineering can bridge this gap with controllable, reproducible, and cost-effective
organotypic models. We were able to combine acellular porcine myocardium and hCM
within (1) 3D Kube minibioreactors and (2) an electromechanical bioreactor with added
glucose for a DCMP tissue engineered models. Within these disease models, some early
alterations in hCM and ECM were seen. While these systems are promising on their own,
a more appropriate platform could be developed by combining these two.
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CHAPTER 7: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE
WORK
7.1 CONCLUSIONS
As the epidemic of diabetes continues to rise, it follows that instances of
cardiovascular

disease,

such

as

diabetic

cardiomyopathy,

hypertension,

and

atherosclerosis in diabetic patients also rise.1,2 Diabetic cardiomyopathy (DCMP) occurs
in diabetic patients as a ventricular dysfunction independent of coronary artery disease,
hypertension or valvular abnormalities.3 Through cascading events over time,
hyperglycemia and dyslipidemia can lead to this myocardial disease. Dyslipidemia leads
to heightened utilization of circulating free fatty acids (FFA) that creates a highly
oxidative environment that supersedes the endogenous antioxidant defense mechanism of
cells,

preceding

oxidative

stress,

lipotoxicity,

autophagy,

and

apoptosis

of

cardiomyocytes.4 Hyperglycemia causes the formation and accumulation of advanced
glycation endproducts (AGEs) in the extracellular matrix, leading to fibrosis. These
alterations in the myocardium can lead to cardiac inefficiency and heart failure.5
Currently, mainly rodent models and two dimensional (2D) cell cultures have
been employed to analyze early changes associated with DCMP. However, there are
notable differences between rodents and humans that provide challenges when studying
DCMP and 2D cultures lack a dynamic, three dimensional (3D) environment crucial to
the progression of this disease.6 As of now, DCMP diagnosis and treatment is lumped in
with other cardiomyopathies and heart failure, with an emphasis on blood glucose
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control.2 Treatments for this disease do not target the source of the problem, only treat the
symptoms. A more accurate model is needed to investigate specific cell type early
cellular and extracellular modifications of DCMP for diagnosis and determine and test
potential therapies. We believe tissue engineering can be used to bridge this gap. The
tissue engineering paradigm can be utilized to developing a reproducible, native-like
tissue engineered model of the myocardium by combining a scaffold, cells, and
biochemical and physical stimuli to model DCMP.
We have shown that tools and methods used in our lab were able to detect known
extracellular matrix (ECM) and cellular changes associated with DCMP in a
streptozotocin (STZ) type 1 diabetic rat model. Furthermore, through examination of
human cardiomyocytes (hCM), we were able to prove that these cells respond to
hyperglycemia within their milieu. These techniques are useful for analyzing and
detecting DCMP alterations in cells and the ECM such as, lipid accumulation,
endogenous antioxidant mechanisms, advanced glycation endproduct (AGE) buildup,
matrix metalloproteinase (MMP) activity, apoptosis, autophagy, endoplasmic reticulum
(ER) stress, and perivascular and interstitial fibrosis.
We produced a physiologically relevant electromechanical bioreactor within our
lab and method for reproducible scaffolds from decellularized porcine myocardium.
Through our in house decellularization procedure of whole porcine hearts, we were able
to remove porcine cells efficiently while keeping important myocardial ECM proteins
such as collagen IV and laminin intact. By designing and 3D printing a tissue slicer,
myocardium was easily extracted for use. This myocardial scaffold supported viable
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hCM for 18 days. Our electromechanical bioreactor sustained hCM seeded on and in
these scaffolds for 14 days at mechanical and electrical physiological conditions. Cells
were aligned, found throughout the scaffolds, and maintained the cardiomyocyte
phenotype. The ECM was found to be unaltered in these dynamic conditions.
We examined cardiac tissue engineered constructs in: (1) a perfusion 3D Kube
minibioreactor and (2) the electromechanical bioreactor customized in our lab. Each
platform contained decellularized myocardium seeded with human cardiomyocytes for
two weeks; “diabetic” conditions were simulated by increased glucose concentration.
Within these models some early alterations of DCMP were seen. We found were able to
better mimic physiological conditions with our electromechanical bioreactor, compared
to static and non-diabetic conditions, as well as to 2D cell culture.
Our electromechanical tissue engineering platform shows promise for unveiling
early cellular and matrix modifications in DCMP. The potential for this system is
enormous; it could be useful for studying other cardiac diseases in many human cell
types, testing potential therapies and drugs, and preconditioning tissue engineered
myocardium prior to implantation.
7.2 Project Challenges and Considerations
Challenges in this project arose in seeding cells into decellularized porcine
myocardium. Injection seeding of myocardium resulted in pockets of cells within the
scaffold, which does not resemble the highly populated native myocardium. Dynamic
stimulation, either perfusion or electromechanical, for the duration of 14 days did not
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promote homogenous hCM migration into the scaffold. Cell seeding strategies are being
investigated under other projects within our lab.
Another challenge during this project was related to protein analysis of tissues
cultured in the 3D Kube minibioreactor system. The tissue housed within 3D Kubes are
very small and only so many cells can be seeded on them, this led to very low protein
amounts. Protein lysates needed to be concentrated with spin columns before protein
analysis with western blotting to be able to load 20ug per well. This limited proteins that
were analyzed and led to a lower n-value.
Our electromechanical bioreactor was able to house larger scaffolds seeded with
hCM, which mitigated the protein analysis problem seen with the 3D Kube
minibioreactor. This system, however, is not perfusion based, so media was changed
every day. As DCMP and diabetes progress by the accumulation of proteins and toxic
intermediates, this platform may not allow for early alterations in cells and the ECM to
occur. This is currently being developed within our lab.
A consideration for future DCMP models would include; the addition a known
amount of lipids in media with the hyperglycemic environment to simulate dyslipidemia;
increase in pressure to mimic hypertension; and addition of high cholesterol. Other
Another consideration would be employing insulin to simulate a diabetic state with
treatment to determine if cells are still altered. Fibroblasts should also be investigated in
future research, as they are vital players in ECM turnover, are adversely affected in
diabetes, and secrete important paracrine factors. More timepoints should be studied to
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see when cellular and matrix changes are occurring. Microarrays for gene analysis would
be useful for this. For a diagnostic potential, media should also be investigated for
markers that could be targets for patient blood testing.
7.3 Recommendations for Future Work
7.3.1 Analysis of Perfusion Electromechanical Platform
The electromechanical bioreactor is now being modified to be perfusion based
within our lab as of now. Testing of this platform will be performed to ensure hCM and
human cardiac fibroblasts (FBs) maintain phenotype and the ECM is not adversely
affected. hCM and FBs will be cultured and expanded until enough cells needed for
seeding are reached. Decellularized porcine myocardium will be extracted with the tissue
slicer, sterilized with peracetic acid, and left overnight in media (Dulbecco’s modified
eagle medium, 10% fetal bovine serum, 1% antibiotic/antimycotic) at 37 degrees Celsius.
Scaffolds will either be seeded with 3 million hCM or hFB per scaffold via dropwise and
injection seeding. Some scaffolds will be seeded with both hCM (1.2 million; 40%) and
hFB (1.8 million; 60%). Controls will have no cells. They will sit statically in the
incubator for 1 hour, then 4mL of media will be added. Seeded scaffolds will remain in
the incubator, static, for 3 days, with media changes each day. A PrestoBlue and
live/dead assay will be performed as a checkpoint at this time.
After this duration, scaffolds will be placed within modified 6-well plates of the
perfusion electromechanical bioreactor system housed in an incubator and for two days
will be subjected to a 0-40-0 mmHg waveform, followed by two days at 0-80-0 mmHg.
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Once this conditioning period is complete, myocardial-like tissue will be exposed to the
0-120-0 mmHg waveform with electrical stimulus. Static scaffolds in 6 well plates will
be run in tandem as a control with 4mL of media changed every two days. Media in the
electromechanical perfusion system will be changed once a week with supplemental
antibiotic injections 3.5 days after media changes. Media will be collected from static and
dynamic groups every week and frozen for examination.

Perfusion Electromechanical Bioreactor
Groups
Samples Per Timepoint (2,4,6,8 weeks)
Static or Dynamic Cells on Scaffold Histology; Protein; RNA PrestoBlue & Live/Dead
Static
hCM
5
1
Static
hFB
5
1
Static
hCM + hFB
5
1
Static
No cells
5
1
Dynamic
hCM
5
1
Dynamic
hFB
5
1
Dynamic
hCM + hFB
5
1
Dynamic
No cells
5
1
Table 7.1: Sample analysis of perfusion electromechanical bioreactor.

Figure 7.1: Diagram of dissection of scaffolds for analysis.
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Timepoints analyzed will be two, four, six, and eight weeks. In order to have a
high and desired n-value outlined in Table 7.1, this experiment will need to be performed
four times. One myocardial-like tissue from each group will be assessed by PrestoBlue
and a live/dead assay to determine cell viability at each timepoint. Scaffolds will be
dissected as shown in Figure 7.1. Half of each scaffold will be placed in 10% formalin
for 48 hours, processed, embedded, and sectioned to 5um on slides. Slides will be stained
with hematoxylin and eosin, Movat’s pentachrome, Masson’s trichrome, and
immunohistochemically stained for: cardiomyocyte markers such as, sarcomeric αactinin, connexin 43, desmin, and GATA-4; fibroblast markers such as vimentin, prolyl
4-hydroxylase, and heat shock protein 47; and ECM proteins such as, collagen IV and
laminin. One-fourth of each myocardial-like tissue will be used for protein isolation and
flash frozen before stored in the -80-degree Celsius freezer until extraction via
homogenizer and radioimmunoprecipitation assay (RIPA) buffer. Total protein from
these samples will be determined by bicinchoninic acid (BCA) assay. Western blotting
protein for cardiomyocyte markers such as, sarcomeric α-actinin, connexin 43, desmin,
and GATA-4, and ECM proteins such as, collagen IV and laminin will be investigated.
Matrix metalloproteinase (MMP) activity will be examined in media and lysates by
gelatin zymography. One-fourth of each scaffold will be flash frozen and stored in -80degree Celsius freezer for ribonucleic acid (RNA) isolation. RNA samples will be sent
away for microarray analysis for cardiomyocyte genes such as, GATA4 and myosin
heavy chain-β; fibroblast genes such as, vimentin, collagen I and III, and fibroblast
specific protein 1; and any other genes of interest.
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7.3.2 Preliminary Dyslipidemic and High Cholesterol Testing
Preliminary testing of addition of FFAs and cholesterol will be performed to
determine if they harm cell viability in culture. hCM and hFBs will need to be cultured in
serum free conditions, so known amounts of cholesterol and FFAs can be added. hCM
and hFBs (2:3 seeding ratio), hCM alone, and hFB alone will be cultured in 48 well
plates and subjected to various conditions for 12, 24, 48, and 72 hour, and 1 and 2 week
timepoints for viability and cytotoxicity with PrestoBlue, live/dead, and MTS assays.
Cholesterol (Sigma-Aldrich, catalogue #: C3045) will be dissolved in ethanol and added
to serum free media in a range of normal at 1g/L (100mg/dL) to high at 2.5g/L
(250mg/dL) cholesterol. Palmitic acid (Sigma-Aldrich, catalogue #: P0500) and oleic
acid (Sigma-Aldrich, catalogue #: O1008), main fatty acids in human nutrition, will be
conjugated to bovine serum albumin and added to serum free media in a range from
0.25mmol/L to 0.5mmol/L, as previously studied.7 Final concentrations in media will be
assessed after sterile filtration with colorimetric enzymatic assays LabAssay™
Cholesterol and LabAssay™ Phospholipid (FUJIFILM, Wanko Chemicals) before
addition to cells. Conditions and analysis will be performed as shown in Figure 7.2 and
Figure 7.3.
Once testing determines optimal high and normal concentrations of cholesterol
and FFAs in cell culture, secondary preliminary testing will assess these in the two cell
types (hCM + hFB, hCM, and hFB) with combinations of these in normal (1g/L) and
high (4.5g/L) glucose at the same timepoints (12, 24, 48, and 72 hours, and 1 and 2
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weeks). Cell viability and cytotoxicity with be analyzed with PrestoBlue, live/dead, and
MTS assays at these timepoints as shown in Figure 7.4.

Figure 7.2: 48 well plate layout of cholesterol testing. One plate for each timepoint and one cell
type or combination. MTS=MTS assay. L/D=live/dead. PB=PrestoBlue.

Figure 7.2: 48 well plate layout of FFA testing. One plate for each timepoint and one cell type or
combination. MTS=MTS assay. L/D=live/dead. PB=PrestoBlue.
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Figure 7.4: 48 well plate layout of combinational testing. One plate for each timepoint and one
cell type or combination. MTS=MTS assay. L/D=live/dead. PB=PrestoBlue.

7.3.3 Perfusion Electromechanical Platform: DCMP Model
The same dynamic experimental setup described in 7.3.1 will be used, however in
order to model a “diabetic” environment, glucose will be added (4.5 g/L), along with high
FFAs and cholesterol (determined in 7.3.2) to serum free media in the perfused
electromechanical bioreactor. Normal serum free media (1 g/L glucose, normal FFAs and
cholesterol) will be run in tandem as a control. All scaffolds seeded with hCM, hFB, and
hCM and hFB will be conditioned as described before, then subjected to physiological
conditions in the perfused electromechanical system. Timepoints analyzed will be two,
four, six, and eight weeks at normal and “diabetic” conditions for all three cell groups
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(Table 7.2). Media will also be collected and samples at two, four, six, and eight weeks
will be analyzed. Multiple bioreactor runs will be done for a high n-value and separate
runs will be done for normal and “diabetic” conditions. A total of 8 runs will be
performed (normal vs. “diabetic” at four timepoints). A PrestoBlue and live/dead assay
will be used to determine cell viability at these timepoints in normal and “diabetic”
groups. Myocardial-like tissue will be saved for paraffin and frozen cryosection
histological staining, protein, and RNA analysis as shown in Figure 7.1 and Table 7.2.
Examination of DCMP hallmarks such as lipid accumulation, endogenous antioxidant
mechanisms, AGE buildup, MMP activity, apoptosis, autophagy, ER stress, and fibrosis
will be completed as detailed in Chapter 6. Tissue and media will be sent away for
microRNA analysis.

Run
1
1
1
2
2
2

Perfusion Electromechanical Bioreactor
Groups
Samples Per Timepoint (2,4,6,8 weeks)
Condition Cells on Scaffold Histology; Protein; RNA PrestoBlue & Live/Dead
Normal
hCM
7
1
Normal
hFB
7
1
Normal
hCM + hFB
7
1
"Diabetic" hCM
7
1
"Diabetic" hFB
7
1
"Diabetic" hCM + hFB
7
1

Table 7.2: Sample analysis of perfusion electromechanical bioreactor DCMP model.
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Appendix A
Abbreviations
2D

two dimensional

3D

three dimensional

ABS

acrylonitrile butadiene styrene

ACE

angiotensin converting enzyme

ADSC

adipose derived stem cell

AGE

advanced glycation endproduct

Akt

protein kinase B

ATF4

activating transcription factor 4

ATF6

activating transcription factor 6

ATP

adenosine 5’-triphosphate

BCA

bicinchoninic acid protein assay

BiP

binding protein

BMDSC

bone marrow derived stem cell

CD36

cluster of differentiation 36

CHOP

CCAAT/-enhancer-binding protein homologous protein

CM

cardiomyocyte

cm

centimeters

CML

carboxymethyl lysine

CPC

cardiac progenitor cell

CSC

cardiac stem cell
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DAPI

4’,6-diamidino-2-phenylindole

DAQ

data acquisition

DCMP

diabetic cardiomyopathy

ddH2O

distilled deionized water

Decell

decellularization

DMEM

Dulbecco’s modified eagle medium

DNA

deoxyribonucleic acid

DPP-4

dipeptidyl peptidase inhibitor

DSC2

desmocollin-2

EC

endothelial cell

ECM

extracellular matrix

EDTA

Ethylenediaminetetraacetic acid

eIF2α

eukaryotic translation initiation factor 2 alpha

eNOs

endothelial nitric oxide synthases

EPC

endothelial progenitor cell

ER

endoplasmic reticulum

ERAD

endoplasmic reticulum associated degradation

ESC

embryonic stem cell

FB

fibroblast

FBS

fetal bovine serum

FFA

free fatty acid

g

gram
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GFP

green fluorescent protein

GLP-1

glucagon-like peptide 1

GLUT4

glucose transporter 4

H&E

hematoxylin and eosin

HCl

hydrochloric acid

hCM

human cardiomyocyte

Hz

hertz

ICa-L

L-type calcium ion channel

IHC

immunohistochemistry

iPSC

induced pluripotent stem cell

IRE-1

inositol-requiring enzyme 1

IRS-1

insulin receptor substrate 1

Ito

outward potassium current

JNK

Jun N terminal kinase

JUP

armadillo proteins plakiglobin

L

liter

LC3B

light chain 3B

min

minute

mL

milliliter

mM

millimolar

mmHg

millimeter of mercury

MMP

matrix metalloproteinase
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MRI

magnetic resonance imaging

MSC

mesenchymal stem cell

msec

millisecond

NaCl

sodium chloride

NADPH

nicotinamide adenine dinucleotide phosphate

NCX

Na+2/Ca+2 exchanger

NIH

National Institute of Health

NOS

nitric oxide synthase

Nrf2

(erythroid-derived 2)-related factor2

OCT

optimal cutting temperature

PDK4

pyruvate dehydrogenase kinase 4

PERK

protein kinase RNA-like ER kinase

PET

positron emission tomography

PI3K

phosphoinositide 3-kinase

PKC

protein kinase C

PLB

phosphorylated phospholamban

PPAR- α

peroxisome proliferator-activated receptor alpha

RAGE

receptor for advanced glycation endproducts

RDU

relative densitometry units

RGD

arginylglycylaspartic acid

RIPA

Radioimmunoprecipitation assay

RNA

ribonucleic acid
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ROS

reactive oxygen species

RyRs

ryanodine receptor

sarc. α-actinin

sarcomeric α-actinin

SD

standard deviation

SDS

sodium dodecyl sulfate

SEM

scanning electron microscopy

SERCA

sarcoplasmic/endoplasmic reticulum Ca+2-ATPase

SMC

smooth muscle cell

SOD

superoxide dismutase

STZ

streptozotocin

TGF-β

transforming growth factor-beta

TIMP

tissue inhibitor of matrix metalloproteinase

TNFα

tumor necrosis factor alpha

Tris

tris(hydroxymethyl)aminomethane

TZD

thiazolindinediones

ug

microgram

um

micrometer

UPR

unfolded protein response

UV

ultraviolet

V

volts

XPB-1

X-box binding protein 1

ZDF

Zucker diabetic fatty rat
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α

alpha

α-SMactin

alpha smooth muscle actin
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